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A multifactorial cytochrome P450 2D6 genotype-phenotype prediction model to improve
precision of clinical pharmacogenomic tests
Chairperson: Erica Woodahl
BACKGROUND: CYP2D6 is difficult to accurately genotype due to a large number of
single nucleotide variants (SNVs), indels, and structural variation such as deletions,
duplications, and CYP2D6/CYP2D7 hybrid genes. CYP2D6 targeted genotyping panels
are of limited utility; clinically relevant variants that are not genotyped will be missed.
Sequencing solves this problem but requires additional tools to address structural
variation. The goal of our study was to determine the predictive power of Stargazer, a
novel allele-calling program, which combines SNV/indel calls with structural variation
identification.
METHODS: In a panel of 309 human livers, CYP2D6 diplotypes and activity scores
were initially assigned manually using PGRNSeq SNV/indel data and then reassigned
after inclusion of Stargazer-derived structural variation data. We determined
CYP2D6 activity in human liver microsomes with metoprolol and dextromethorphan as
probe substrates. Then, we used linear regression to assess the relationship between
activity and activity scores assigned using SNV/indel data alone versus SNV/indel +
structural variation data.
RESULTS: Without incorporating structural variation data, diplotypes were incorrectly
assigned for 67 samples (22%); activity scores were incorrect for 26 samples (8.4%).
Structural variants included 23 deletions, 47 duplications, and 39 hybrids. When
diplotypes were assigned based on SNV/indel data alone, activity score explained 31% of
the variation in CYP2D6 activity with metoprolol (R2 = 0.31, p < 0.001) and 36% with
dextromethorphan (R2 = 0.36, p < 0.001). When reassigned with SNV/indel plus
structural variation data, this increased to 36% for metoprolol (R2 = 0.36, p < 0.001) and
41% for dextromethorphan (R2 = 0.41, p < 0.001).
CONCLUSION: The accuracy of CYP2D6 phenotype prediction can be improved by
using a next-generation sequencing approach coupled with a tool such as Stargazer to
detect common and rare SNVs and indels as well as structural variation in CYP2D6.
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1 Introduction
1.1 Pharmacogenomics
Pharmacogenomics is the study of how an individual’s genetics affect their
response to drugs, in terms of efficacy and/or toxicity.1 Clinically, pharmacogenomics is
used to optimize drug therapy by guiding the selection of a drug and dose that will
maximize efficacy and minimize adverse effects. Pharmacogenetic tests may be used to
assess genetic variation in drug-metabolizing enzymes or transporters, components of the
immune system that may contribute to idiosyncratic adverse drug reactions, or genes
involved in a drug’s mechanism of action. 2
1.1.1

Translation from bench to bedside: an unmet need
The publication of Arno Motulsky’s 1957 paper Drug reactions, enzymes, and

biochemical genetics is generally regarded as the beginnings of pharmacogenomics as a
discipline.3 In this paper, he discussed “how hereditary gene-controlled enzymatic factors
determine why, with identical exposure, certain individuals become ‘sick,’ whereas
others are not affected.” In 1959, two years after Motulsky’s publication, Friederich
Vogel coined the term “pharmacogenetics.” The term “pharmacogenomics” has since
been introduced and reflects advances in knowledge and technology that allows
investigation of the entire genome. 1,3
Despite a long history, the field of pharmacogenomics is only starting to move
into the clinical setting. Both the United States Food and Drug Administration (FDA) and
the National Institutes of Health (NIH) have recognized the potential behind precision
medicine and have launched initiatives to support the necessary scientific and regulatory
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structure.4 One mechanism used by the FDA is inclusion of pharmacogenetic data on
drug labels. Specifically, this includes information that “has important implications for
safe and effective use and the consequences of the genetic differences result in
recommendations for restricted use, dosage adjustments, contraindications, or warning.”5
Simply including this information on the label, however, may not be enough to encourage
clinicians to use pharmacogenetic testing to guide clinical decision-making. In 2014,
Wang et al. reviewed the FDA 199 drug labels that included pharmacogenetic data. Of
these, only 43 (36.1%) provided convincing evidence of clinical validity. Additionally,
only 61 (51.3%) of the labels made any recommendation about how to use the results of a
pharmacogenetic test.6 This study highlights the prerequisite need to provide clear,
evidence-based recommendations to clinicians if they are to use pharmacogenetic tests in
practice.
Studies investigating clinician’s attitudes towards the utility of
pharmacogenomics in clinical practice further demonstrate the need to refine the way
pharmacogenomics data is presented. A 2015 survey of 90 Mayo Clinic primary care
physicians found that 52% of the clinicians did not expect or know whether they would
use pharmacogenomics information for future prescribing. Furthermore, 53% reported
that the pharmacogenomics Clinical Decision Support alerts integrated into the Mayo
Clinic’s electronic health records software were, “confusing, irritating, frustrating, or
difficult to use.” Of those who received a Clinical Decision Support alert, only 30%
altered their original prescription.7 Even at a site such as the Mayo Clinic that has
implemented a dedicated pharmacogenomics program, clinicians are often still not
getting the information they need delivered in the right way.
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Initial results from the University of Chicago’s 1200 Patients Project suggest that
a more streamlined process may improve acceptance of pharmacogenomics
recommendations among physicians. The 1200 Patients Project uses the Genomics
Prescribing System (GPS) to provide alerts to physicians. When there is a
pharmacogenomics alert for a specific patient, the prescriber will see a graphic of a
stoplight with a red, yellow, or green light, indicating the severity of the results. Upon
clicking on the stoplight, a summary that can be read in 30 seconds or less describes the
drug/gene interaction. Initial results published after 812 patients had been enrolled
indicated that physicians clicked on the red light alert 100% of the time, the yellow light
alert 72% of the time, and the green light alert 20% of the time. When surveyed after an
alert prompted a medication change, 10% agreed strongly with the GPS recommendation,
76% agreed somewhat, 3% disagreed somewhat, and 10% disagreed strongly.
Furthermore, 93% of respondents said that they were “very likely” to enroll more of their
patients in the study.8
To address issues involved with efficient delivery of usable information, groups
composed of clinicians, academics, and industry representatives, such as the Clinical
Pharmacogenomics Implementation Consortium (CPIC), have been formed to with the
goal of developing clinical practice guidelines for pharmacogenomics test interpretation.
Similar groups exist internationally such as the European Pharmacogenetics
Implementation Consortium (Eu-PIC) and the Dutch Pharmacogenetics Working Group
(DPWG). The primary activity of the CPIC is to publish “freely available, peer-reviewed,
updatable, and detailed gene/drug clinical practice guidelines” that “enable the translation
of genetic laboratory test results into actionable prescribing decisions for specific drugs.”9
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As of January 2018, the CPIC has published guidelines for 36 different drug/gene
combinations. Some of the guidelines are for a single drug/gene pair, such as codeine and
CYP2D6, while others are for a drug and a combination of genes, such as warfarin and
CYP2C9 and VKORC1.10 Each guideline conforms to a standardized format and system
to grade levels of evidence and to score the strength of each prescribing recommendation.
The guidelines contain a literature review, information on the gene of interest, a summary
of available genetic tests, guidance on how to interpret genetic tests, information on the
drug of interest, and specific recommendations for drug or dose changes based on genetic
test results. Numerous citations in the literature as well as formal endorsement by the
American Society of Health-System Pharmacists (ASHP) are favorable indications of
CPIC guideline uptake.11
1.1.2

Drug-metabolizing enzymes and transporters
The absorption, distribution, metabolism, and elimination of drugs and other

xenobiotics is mediated by drug-metabolizing enzymes and drug transporters. Drugmetabolizing enzymes are responsible for phase I and phase II of drug metabolism. Phase
I consists of oxidation, reduction, and hydrolysis reactions, 75% of the reactions
catalyzed by cytochrome P450 enzymes. Phase II consists of the conjugation of
endogenous hydrophilic moieties by transferase enzymes. Transporters are involved with
absorption, distribution, and elimination of drugs and metabolites.
Variability in drug response and toxicity is multifactorial, with sources such as
genetics, age, environmental factors, disease states, and drug-drug interactions all playing
a role. Of these factors, the genetics of drug-metabolizing enzymes and drug transporters
make a large contribution. Studies have found that interindividual variability in function
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for drug-metabolizing enzyme and transporter genes is higher than that in genes not
related to drug metabolism or transport. In a study that examined protein expression
levels in a cohort of 427 liver samples, a 641-fold difference was observed between the
highest and lowest expression levels of CYP3A4, a phase I enzyme. For glutathione S
transferase A1, a phase II enzyme, a 582-fold difference was observed.12
Pharmacogenomics offers a means to explain these differences.
1.1.2.1 Phase I Drug Metabolism
Phase I drug metabolism occurs mostly in the liver, with most phase I enzymes
located in hepatocyte endoplasmic reticulum membranes. Phase I reactions include
oxidation, reduction, and hydrolysis, with oxidation being the most common. These
reactions convert lipophilic drugs into more easily excreted hydrophilic compounds. The
cytochrome P450 (CYP) family of drug-metabolizing enzymes is responsible for most
phase I metabolism.13
There are 57 functional human CYP enzymes, grouped into 18 families and 44
subfamilies. Of these, about a dozen enzymes from families 1, 2, and 3 are responsible
for the metabolism of 70-80% of all clinically used drugs. There is a wide range of
variability in drug-metabolizing enzyme activity between individuals. This variability is
often multi-factorial and dependent on factors such as age, sex, and disease state. For
some CYP genes, genetic polymorphisms are a major determinant of variability. In the
context of drug metabolism, loss-of-function variants can result in decreased drug
clearance of the parent compound while gain-of-function variants can result in increased
drug clearance.14
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1.1.2.2 Phase II Drug Metabolism
Phase II metabolism also occurs primarily in the liver. Some phase II enzymes are
cytosolic while others are located in hepatocyte endoplasmic reticulum membranes.
Phase II reactions are conjugation reactions that increase the hydrophilicity of the parent
compound or primary metabolite. Enzymes include UDP-glucuronosyltransferases
(UGTs), sulfotransferases (SULTs), N-acetyltransferases (NATs), glutathione Stransferases (GSTs), and methyltransferases, primarily thiopurine S-methyl transferase
(TPMT) and catechol O-methyl transferase (COMT).15 The most prominent phase II
enzymes are the UGTs, which glucuronidate 40-70% of all clinically used drugs. Of the
four UGT families identified in humans, UGT1 and UGT2 are involved in the
glucuronidation of xenobiotics.15
1.1.2.3

Drug Transport
Compared to drug-metabolizing enzymes, there are fewer clear pharmacogenomic

associations between genetic variation in drug transporter genes and drug efficacy and/or
toxicity.16 Major families of drug transporters include ATP binding cassette (ABC) and
solute carrier (SLC and SLCO) transporters.
Key transporters in the ABC family are P-glycoprotein (MDR1/ABCB1), breast
cancer resistance protein (BCRP/ABCG2), multidrug resistance proteins (MRPs/ABCCs).
Of these transporters, clinical evidence is the best for BCRP pharmacogenetics. BCRP,
encoded by ABCG2, is an efflux transporter expressed in the liver, intestine, the kidney,
and in blood-tissue barriers. Over 180 variants have been identified in the ABCG2 gene
but only a handful have been associated with variation in function, expression, mRNA
stability, or clinical outcomes. The most studied variant, 421C>A affects transport rates
of statins and possibly tyrosine kinase inhibitors. 17,18 ABCB1, the gene that encodes the
11

efflux transporter P-glycoprotein (P-gp), is highly polymorphic but there is conflicting
evidence on whether ABCB1 genotype has any influence on drug plasma levels or clinical
outcomes. 16,18
SLC drug transporters include but are not limited to organic anion transporters
(OATs), organic cation transporters (OCTs), peptide transporters (PEPTs) and organic
anion transporting polypeptides (OATPs).17 A notable pharmacogenetic association exists
for hepatic uptake transporter OATP1B1, encoded by gene SLCO1B1, and the lipidlowering agent simvastatin. Simvastatin is a major substrate of OATP1B1, and patients
carrying an allele containing the 521T>C variant (*5, *15, or *17) are at higher risk of
statin-related myopathy due to increased plasma and peripheral drug levels. A CPIC
guideline has been published for SLCO1B1 with the recommendation to prescribe lower
starting doses or alternative statins for individuals heterozygous or homozygous for
decreased-function alleles. 19,20
1.1.3

Applications
Pharmacogenetics was initially implemented in the clinic via single-gene tests

ordered if a physician was considering prescribing a drug with an actionable
pharmacogenetic association or to guide therapy changes after treatment failure or
unacceptable toxicity. This remains the most widespread method of pharmacogenetic
testing.21 The FDA requires pharmacogenetic testing for certain drug/gene pairs and
groups such as CPIC provide guidance documents on additional drugs or genes with
pharmacogenetic indications.
Some large medical institutions have implemented preemptive
pharmacogenomics programs where genetic testing is done on multiple pharmacogenes
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when a patient enters into a healthcare system. The data is placed in their electronic
medical record and is available if they are ever prescribed a drug with an actionable
pharmacogenetic association.22
1.1.3.1 FDA-required pharmacogenetic tests
The FDA currently requires genetic testing for 52 drugs and recommends it for 4
more. A test is classified as “required” if the label states that a test “should be
performed.” In some cases, an FDA-approved companion diagnostic test must be
performed before a patient is initiated on a drug. In other cases, the requirement is up to
the discretion of the provider. A test is classified as “recommended” if the label states
that it “should be considered.” 23,24
The majority of drugs with required genetic testing are kinase inhibitors and
monoclonal antibodies used in oncology. Generally, the genetic tests are for determining
whether tumor cells contain specific genetic mutations that make them sensitive or
resistant to the drug. For example, erlotinib is kinase inhibitor used for treatment of
patients with metastatic non-small cell lung cancer whose tumors have specific mutations
in the epidermal growth factor receptor (EGFR) gene. Only patients who are positive for
the mutations, as determined by an FDA-approved companion diagnostic test, may
receive erlotinib.25 An example of a monoclonal antibody requiring genetic testing is
trastuzumab. Trastuzumab is used in the treatment of HER2-overexpressing breast cancer
and gastric cancer. Prior to initiating therapy, HER2 overexpression must be confirmed
by an FDA-approved fluorescence in situ hybridization (FISH) assay to test gene
amplification.26
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Genetic tests may be required when certain genetic polymorphisms are associated
with higher risks of adverse reactions. Two of these pharmacogenetic associations are
related to mutations in the human leukocyte antigen B (HLA-B) gene. Abacavir, an
antiretroviral drug used to treat HIV/AIDS, is associated with severe hypersensitivity
reactions in patients with the HLA-B*5701 allele and testing for the allele is required
prior to initiation.27 Carbamazepine, an anticonvulsant, has been associated with severe
dermatologic reactions in patients with the HLA-B*1502 allele. This allele is most
common in patients of Asian descent but mostly absent in other populations. Thus, the
FDA states that patients of Asian descent should be screened for HLA-B*1502 prior to
initiating treatment with carbamazepine.28
CYP2D6 is the only CYP enzyme with FDA-recommended and –required testing.
The FDA-required pharmacogenetic tests are used to guide dose selection for CYP2D6
substrates tetrabenazine, eliglustat, and pimozide. The FDA recommends testing to
determine the risk of adverse effects when treating with dextromethorphan/quinidine. For
other CYP enzymes, the FDA provides information about pharmacogenetics but does not
specifically recommend testing. For example, the clopidogrel drug label explains that
efficacy is dependent on conversion to an active metabolite by CYP2C19 and that an
alternative platelet inhibitor should be considered in those identified by genotyping as
having low CYP2C19 activity.29
1.1.3.2 Clinical Pharmacogenomics Implementation Consortium guidelines
To date, the CPIC has published guidelines on 36 drug/gene combinations. Each
guideline includes background information on the gene(s) and drug of interest, available
genetic test options and how to interpret them, data on how genetic variability is linked to

14

drug-related phenotypes, and dosage recommendations.11 The CPIC has also begun
providing resources for integration of pharmacogenomic test results into electronic health
records.30
The guidelines are primarily for drug-metabolizing enzymes, with the majority
focused on CYPs. For CYP2C19, guidelines are available for SSRIs citalopram,
escitalopram, and sertraline, the anti-platelet agent clopidogrel, and the anti-fungal
voriconazole. For CYP2D6, guidelines are available for SSRIs paroxetine and
fluvoxamine, tricyclic antidepressants nortriptyline and desipramine, opioid analgesic
codeine, and anti-emetics odansetron and tropisetron. Some guidelines include
recommendations based on the diplotypes for multiple genes. Guidelines that include
both CYP2C19 and CYP2D6 are for tricyclic antidepressants amitriptyline,
clomipramine, imipramine, trimipramine, and doxepin. Additional guidelines that include
CYPs are published for tacrolimus and CYP3A5, phenytoin and CYP2C9 plus HLA-B,
and warfarin and CYP2C9, CYP4F2, and VKORC1.31
1.1.3.3 Preemptive pharmacogenomics programs
Some healthcare systems have developed preemptive pharmacogenomic testing
programs focused on drug/gene pairs with the strongest evidence. Preemptive
pharmacogenomics involves genotyping a panel of genes related to drug metabolism and
incorporating the data into patients’ electronic medical records. If an actionable drug is
prescribed, the clinician will receive guidance on how to adjust the dose or choose
another drug based on the patient’s diplotype. 21,32
The Pharmacogenomics Research Network (PGRN) Translational
Pharmacogenomics Program (TPP) represents a major effort to implement preemptive
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pharmacogenomics programs in a variety of clinical sites. The sites that are part of TPP
include Mayo Clinic, The Ohio State University, St. Jude Children’s Research Hospital,
University of Florida, University of Maryland, Vanderbilt University Medical Center,
University of Chicago, and Brigham and Women’s Hospital. Each site has developed
programs relevant to the patient population it serves.32
St. Jude Children’s Research Hospital has one of the largest preemptive
pharmacogenetics programs. In 2011, an array-based genotyping test that interrogates
1,936 variants in 230 genes was implemented as part of routine patient care. As new
literature is published, a pharmacogenetics committee decides on which drug/gene pairs
to include in the electronic health record (EHR) system. As of January 2014, genetic data
was included in the EHR for a total of 1,106 patients. Of these patients, 792 (78%) have
at least one actionable drug-metabolizing enzyme diplotype, meaning that a drug or dose
change would be necessary. The drug/gene pairs that are included in the EHR represent
some of the biggest “success stories” in pharmacogenetics: TMPT and thiopurines,
CYP2D6 and codeine, CYP2C9+VKORC1 and warfarin, CYP2C19 and clopidogrel, and
UGT1A1 and irinotecan.33
Vanderbilt University Medical Center’s program, Pharmacogenomic Resource for
Enhanced Decisions in Care and Treatment (PREDICT), was initially focused on
antiplatelet medications in patients who were either anticipating the need for coronary
artery stenting or who had cardiovascular risk scores that suggested they may need
antiplatelets in the future. Since coronary artery stenting is often performed as an
emergency procedure, having pharmacogenetic data available prior to the event expedites
the process of choosing the most efficacious antiplatelet for each specific patient.
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Similarly to the methods used at St Jude, genotyping data is stored outside of the EHR
until a genetic result is deemed actionable by committee. The first diplotype included in
the EHR was CYP2C19*2/*2, which is a poor metabolizer diplotype. Clopidogrel is a
prodrug that must be metabolized by CYP2C19 to an active metabolite. Poor
metabolizers do not produce enough of this active metabolite, resulting in significantly
reduced platelet inhibition and an increased risk for adverse cardiovascular events.
Patients who are CYP2C19 poor metabolizers should receive an alternative antiplatelet,
such as prasugrel or ticagrelor, which is not a CYP2C19-dependent prodrug. 34As of
2013, the PREDICT program has genotyped 10,000 patients and implemented the
following drug/gene pairs in addition to CYP2C19 and clopidogrel:, SLCO1B1 and
simvastatin, CYP2C9+VKORC1 and warfarin, CYP3A5 and tacrolimus, and TPMT and
thiopurines.32

1.2 Cytochromes P450
1.2.1

CYPs responsible for drug metabolism
Cytochrome P450 enzymes are a superfamily of mono-oxygenases responsible for

the metabolism of 70 – 80% of all clinically used drugs. They are the primary contributor
to phase I drug metabolism via the catalysis of oxidative biotransformation reactions.14
CYPs are endoplasmic reticulum-associated membrane-bound enzymes located
hepatically, and to a lesser extent, extrahepatically. There are 57 functional P450 genes
grouped into 18 families and 44 subfamilies. Of these, families 1, 2, and 3 are responsible
for the metabolism of drugs and other xenobiotics. The remaining families have a variety
of functions including, but not limited to, the synthesis of steroid hormones,
prostaglandins, and bile acids. Substrates include sterols, fatty acids, eicosanoids, and
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vitamins. The predominant xenobiotic-metabolizing CYPs in the liver are CYPs 1A2,
2C9, 2C8, 2E1, and 3A4 with 2A6, 2D6, 2B6, 2C19, and 3A5 found less abundantly. 14,35
The CYP1 family contains CYP1A1, CYP1A2, and CYP1A3. Of the three,
CYP1A2 is the most clinically relevant and is responsible for the metabolism for 8.9% of
clinically used drugs. It represents ~4-16% of the total hepatic P450 pool while CYP1A1
and CYP1B1 are expressed extrahepatically. Substrates of CYP1A2 include analgesics
and antipyretics, antipsychotics, antidepressants, anti-inflammatories, and some
cardiovascular drugs. Variation in CYP1A2 activity is primarily due to non-genetic
factors such as enzyme induction via tobacco smoke, charred meat, or cruciferous
vegetables.14
The CYP2 family contains 16 genes physically organized in gene clusters. Genes
relevant to drug metabolism are in families CYP2A-E and CYP2J. The CYP2A family,
consisting of CYP2A6, CYP2A7, and CYP2A13, makes up ~4% of the hepatic P450
pool. Of the three isoforms, CYP2A6 is the most relevant to drug metabolism and has
clinically relevant pharmacogenetic implications. It is the primary enzyme responsible for
the metabolism of nicotine into the inactive metabolite cotinine and individuals with lowactivity alleles have been shown to have higher plasma nicotine levels. The sole member
of the CYP2B family is CYP2B6. It contributes an average of ~2-5% to the total hepatic
P450 pool. The gene is highly polymorphic and CYP2B6 pharmacogenetics are relevant
in the context of HIV treatment. CYP2B6 is the primary enzyme responsible for the
metabolism of efavirenz. Higher plasma levels of efavirenz have been observed in
patients with low-activity alleles, with higher drug exposures associated with
neurotoxicity necessitating treatment discontinuation. The only gene in the CYP2E

18

family is CYP2E1. It is expressed at relatively high levels in adult livers and is
responsible for the metabolism of ~3% of clinically used drugs. Genetic variation does
not make a major contribution to CYP2E1 activity and is instead caused by enzyme
induction, inflammation, and certain disease states such as diabetes and liver disease.14
The CYP2C family contains CYP2C8, CYP2C9, CYP2C18, and CYP2C19.
CYP2C9 is highly expressed in the liver and contributes ~20% of the total hepatic P450
pool. CYP2C8 and CYP2C19 are expressed at 2- and 10-fold lower levels, respectively.
Though it is highly expressed, CYP2C18 does not make large contribution to drug
metabolism. While genetic variation in CYP2C9 and CYP2C19 is clinically relevant, the
clinical impact of genetic variation in CYP2C8 is not clear. CYP2C9 is responsible for
the metabolism of ~13% of clinically used drugs including substrates with narrow
therapeutic indices, such as warfarin. Genetic variation in CYP2C9 and VKORC1 (the
pharmacodynamic target of warfarin) can explain 50-60% of the variation in warfarin
maintenance dose in Caucasian patients. CYP2C19 is responsible for the metabolism of
6.8% of clinically used drugs and is particularly important in the metabolism of
clopidogrel, an anti-platelet agent.14
The CYP2D family consists of CYP2D6, which will be discussed separately in
section 1.3.
The CYP3 family consists of CYP3A4, CYP3A5, and CYP3A7. The most
abundant isoform is CYP3A4. It contributes ~14-24% of the total hepatic P450 pool and
is also the major P450 enzyme in intestinal enterocytes. CYP3A4 metabolizes a wide
variety of substrates and is responsible for the metabolism of ~30% of clinically used
drugs. For these reasons, CYP3A4 is a major contributor to the first-pass metabolism of
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many orally administered drugs. Variability in CYP3A4 activity is influenced by multiple
factors, such as transcriptional induction by xenobiotics, cytokine-mediated downregulation secondary to inflammatory responses, and genetic polymorphisms. Clinically,
genetic variation in CYP3A4 has been demonstrated to be relevant to statin response and
time to reach appropriate steady-state concentrations of tacrolimus and cyclosporine in
transplant recipients.14
CYP3A5 shares high sequence similarity with CYP3A4 and thus similar substrate
selectivity. CYP3A5 is unlike other P450 isoforms in the sense that a non-functional allele
is more common in some populations than the CYP3A5*1 allele. The most common loss
of function allele, CYP3A5*3, is the found at a frequency of 0.88 – 097 in Caucasian
populations and 0.66 – 0.75 in Asians and Hispanics. In people of African descent, the
CYP3A5*3 allele is not as predominant and is found at a frequency of 0.12 – 0.35 in
Africans and 0.37 in African Americans.14
CYP3A7 is the fetal form of CYP3A and accounts for 50% of total P450 protein
content in fetal livers. It has similar substrate specificity as CYP3A4 and CYP3A5. After
birth, CYP3A expression shifts from CYP3A7 to CYP3A4, but some individuals express
CYP3A7 into adulthood due to a mutation in the promoter region that increases
transcription factor binding. The clinical significance of this polymorphism is not well
known.14
1.2.2

Biochemistry
All cytochrome P450 enzymes are hemoproteins. The presence of iron heme

allows the enzyme to utilize oxygen and electrons to ultimately release a molecule of
water and transfer an oxygen atom to a substrate.36
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The overall CYP reaction can be represented as follows:

S + O! + 2!! + 2H ! → H! O + SO

Cytochrome P450 oxidoreductase (POR) and nicotinamide adenine dinucleotide
phosphate (NADPH) are cofactors involved in transfer of electrons to CYPs. POR is a
membrane-bound protein that is in the diflavin oxidoreductase enzyme family. In a single
polypeptide, it contains one molecule of flavin adenine dinucleotide (FAD) and one
molecule of flavin mononucleotide (FMN). NADPH transfers two electrons in the form
of a hydride ion to FAD, which then transfers them one by one to FMN which in turn
transfers electrons one by one to the heme in the P450 enzyme.37
The P450 catalytic cycle begins when a substrate enters the active site and
displaces the water molecule bound to the heme. Electron transfer from POR via NADPH
causes the reduction of iron(III) to iron(II). Next, molecular oxygen binds to the iron to
form a dioxygen adduct. One electron from the iron(II) center and one electron from the
oxygen pair form the iron(III)-oxygen bond. The next reduction step, transfer of a second
electron from POR via NADPH, is the rate-limiting step for many P450 enzymes. In this
step, a negatively charged iron(III)-peroxo complex is formed as an intermediate. The
peroxo group is then rapidly protonated to produce a nucleophilic iron(III)-hydroperoxo
complex. A second protonation generates a molecule of water and an electrophilic
iron(IV)-oxo species that then oxidizes the substrate. The substrate dissociates and the
cycle can start over again.38
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Differences in active site size and conformation confer substrate specificity.
P450s in the CYP1A and CYP1B families have narrow, rigid active sites that
accommodate planar molecules such as polynuclear aromatic hydrocarbons. CYP3A4
metabolizes a much wider range of substrates and this is reflected in the differences in its
active site. CYP3A4 has a large and open active site cavity that allows for more exposure
to the heme surface. Also, its active site is not rigid and can expand and contract to
accommodate substrates of different size. Of the enzymes in the CYP2 family, CYPs
2E1, 2A6, and 2B6 have small active site cavities and CYPs 2C8, 2C9, 2C19, and 2D6
have large active site cavities. The enzymes with larger active site cavities metabolize a
wider range of substrates. Differences within enzyme families confer further substrate
specificity. CYP2C19, for example, has two internal cavities. The first is positioned
above the surface of the heme where reactive intermediates are formed and the second is
an adjacent antechamber that may represent a substrate access channel. CYP2C8, on the
other hand, contains only one large cavity. Most P450s have a single substrate-binding
site but some can bind more than one substrate molecule, either in the active site or in an
allosteric site. 39,40
1.2.3

Principles of in vitro P450 reaction phenotyping
The enzyme kinetic parameters Vmax, Km, and CLint can be determined using liver-

based in vitro P450 reaction assays. The data obtained from these assays can then be used
to assess topics such as the clearance of investigational drugs, the effects of drug-drug
interactions, and the effects of genetic polymorphisms on drug clearance.41
Vmax refers to the theoretical maximum rate of an enzymatic reaction and occurs
when the enzyme is saturated with substrate. The Michaelis constant, Km, represents the
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substrate concentration that yields a reaction velocity that is one half of Vmax. An enzyme
with high affinity for a substrate will have a low Km value, meaning that 50% of the
enzyme molecules will be bound to substrate at a relatively low concentration. Vice
versa, an enzyme with a low affinity for a substrate will have a high Km value. 41,42
Values for Km and Vmax are determined experimentally by incubating enzyme
with substrate at a range of concentrations. When the rate of the reaction (v) is plotted
against the concentration of substrate ([S]), the result is a hyperbolic curve that can be
described using the Michaelis-Menten equation.43

𝑣=

𝑉!"# × [𝑆]
𝐾! + [𝑆]

1.2.3.1 In vitro models of drug metabolism
Numerous liver-based methods are used for in vitro investigation of hepatic drug
metabolism. In vitro models include isolated perfused livers, liver slices, isolated or
cultured hepatocytes, recombinant enzymes, and human liver microsomes (HLMs). Each
model has its own particular advantages and disadvantages.44 HLMs are the most popular
model for studying drug metabolism and thus will be discussed more in-depth in this
section.
The use of isolated perfused livers offer the best representation of in vivo
conditions but use is limited to animal models due to the scarcity of whole human livers.
Isolated perfused livers are not generally used to assay CYP-mediated drug metabolism.
Due to the presence of functional bile canaliculi, they are most useful for transporter
assays when the biliary excretion of a drug is being investigated. Liver slices offer similar
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advantages to isolated perfused livers: the presence of drug-metabolizing enzymes,
transporters, and functional bile canaliculi. However, it is more difficult to collect bile
from liver slices and the presence of necrotic cells may limit drug transporter assays.
Furthermore, liver slices are not always practical since CYP expression decreases >50%
within 24 hours of preparation and tissue perfusion by the substrate is limited.44
Isolated primary hepatocytes are easier to procure and use than whole livers or
liver slices and offer a good representation of in vivo activity since they reflect natural
heterogeneity in CYP expression. A disadvantage is that isolated primary hepatocytes are
only viable for 2-4 hours. Cryopreserved human hepatocytes are available commercially
and may be cultured for up to four weeks. However, CYP expression decreases with time
and can introduce unwanted variability.44
Recombinant systems use transgenic human cell lines, bacteria, or yeast to
express recombinant CYP enzymes. These systems are advantageous over hepatocytes
since the cells are easier to culture and can be designed to express a single CYP, which is
useful if a model focused on a single enzyme is desired. A disadvantage is that data
obtained from studies using recombinant systems may be difficult to extrapolate to in
vivo conditions.44
HLMs are vesicles of hepatocyte endoplasmic reticulum obtained by differential
centrifugation of liver tissue or primary hepatocytes. HLMs contain CYP enzymes as
well as other endoplasmic reticulum-associated drug-metabolizing enzymes such UGTs,
flavin monooxygenases, carboxyl esterases, and epoxide hydrolase. Advantages to using
HLMs for studying CYPs in vitro is that they are cheap, are relatively easy to use, can be
frozen and stored for years, and allow study of inter-individual variability. A
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disadvantage to using HLMs is that in vitro-in vivo extrapolation is limited by the fact
that contributions from drug-metabolizing enzymes not present in the endoplasmic
reticulum fraction are not accounted for. Furthermore, cytosolic cofactors involved in
CYP reactions must be added to the system exogenously.44,45
HLMs are available commercially as pooled preparations or through liver banks
as single-donor preparations and the choice to use one or the other depends on the goals
of a particular study. Pooled products are useful when the goal of a study is to reduce
interindividual variability and assess how a population as a whole metabolizes a
xenobiotic. HLM pools can be designed to be representative of a broad population, such
as Americans as a whole, or subpopulations, such as African Americans. They can also
be designed to include HLMs from, for example, only donors genotyped to be CYP2D6
poor metabolizers. In the latter case, a more specific population is being studied, but
pooling several donors theoretically results in a HLM product that is representative of the
average. Single-donor HLMs are used when the goal of a study is to investigate
interindividual variability in drug-metabolizing enzymes. In these types of studies,
deviations in enzyme activity from average population levels are of particular interest so
pooling several samples would be counterproductive. 45,46
1.2.3.2 Human liver microsome incubations
In vitro assays with HLMs involve incubating the HLMs with a probe substrate,
NADPH, and a phosphate buffer at 37 °C for a specified amount of time in a shaking
water bath. After stopping the reaction by adding a protein precipitating reagent such as
ice cold acetonitrile, either metabolite formation or substrate depletion is quantified using
methods such as LC-MS/MS.45
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A number of methodological considerations must be made when carrying out
HLM incubations. NADPH should not be a rate-limiting reagent and should be used at
saturating concentrations of 0.5 – 1 mM. The incubation should be carried out in
physiologically relevant conditions through the use of phosphate buffers at a
concentration of 50 – 100 mM, a pH of 7.4, and a temperature of 37 °C.43
The ability to calculate intrinsic clearance requires the reaction to be run under linear
conditions. Methodological factors that determine linearity include enzyme
concentration, substrate concentration, and incubation time. Enzyme concentrations must
be much less than the substrate concentration to ensure that the reaction rate does not
slow due to reduced substrate availability or through product inhibition. A generally
accepted number is a 5% reduction in substrate during the course of the assay. At the
same time, substrate concentration must be low enough to ensure that [S] << Km.
Incubation time should be selected in a way that results in negligible product formation
relative to substrate concentrations. Incubation time is of further concern since short
incubations can be impractical and long incubation times can cause enzyme and substrate
degradation.43
When a Km value for a specific substrate can be obtained from the literature,
optimization of incubation conditions is relatively simple. Ideally, 8-10 different substrate
concentrations that span the range of one tenth to ten-fold of the Km value is ideal, though
one fifth to five-fold is suitable if there are limitations related to solubility or analytical
methods. While keeping the substrate concentrations constant, enzyme concentration and
incubation time can be varied to fit the considerations discussed above. From these data
points, the kinetic data can be plotted and the most appropriate substrate concentration,
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enzyme concentration, and incubation time can be selected for further assays.43
Two distinct experimental approaches, metabolite formation and substrate
depletion, are used for kinetic experiments. Metabolite formation is the traditional
approach used to determine CLint. This approach uses short incubation times and low
enzyme concentrations to fulfill the assumption of minimal substrate consumption. The
disadvantage to the metabolite formation approach is that the metabolic pathway must be
known. When the metabolic pathway of a drug is not known, the substrate depletion
approach may be useful. However, with this approach, at least 20% of the substrate must
be metabolized, requiring longer incubation times and higher enzyme concentrations.
This increases the likelihood of product inhibition and degradation of the substrate and/or
enzyme. Furthermore, studies to determine linearity are not often performed so CLint
values obtained using a substrate depletion approach may have poor in vivo predictive
utility.47
1.2.4

Allele nomenclature
An allele is a variant form of a gene. Humans are diploid organisms, meaning

they have two alleles at each genetic locus.48 Some alleles consist of a single nucleotide
variant (SNV) occurring in either a coding (exonic) or non-coding (intronic) region of the
gene. SNVs can also occur in the promoter region or in upstream or downstream
untranslated regions flanking the gene. Alleles can be defined by the presence of
insertions/deletions (indels), splicing variations, or structural variation like gene
deletions, duplications, and recombinations. Alleles can also represent haplotypes, or a
cluster of SNVs that are inherited together.49
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Each P450 gene has its own allele nomenclature that is based off of historical
naming conventions. The Pharmacogene Variation Consortium (PharmVar) has sought to
standardize P450 naming with a star allele nomenclature system. In this system, a
common allele conferring normal activity is defined as the reference allele for a particular
CYP gene and is designated as the *1 allele (e.g. CYP2D6*1). Variant alleles are
compared to the *1 allele and given their own star name (e.g. *2, *3, etc.) upon approval
of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Some alleles
have one or more suballeles (e.g. *2A, *2B, *2C) if they share a common defining
polymorphism, such as a SNV resulting in a loss of function, but vary in any additional
polymorphisms that do not appreciably change protein function.50
An individual’s diplotype represents both alleles at the gene locus of interest. An
example of a diplotype would be *1/*2, which indicates that the individual has one copy
of the *1 allele and one copy of the *2 allele.
1.2.5

Translating CYP diplotype to phenotype
A barrier to the wide-scale implementation of pharmacogenomics has been the

ability to translate of genetic data into information that is clinically useful. Translational
research is focused on the “bench-to-bedside” process of moving knowledge gained
through basic science research into medical practice.51 With pharmacogenomics, this
involves using genotyping data to make predictions about the way an individual will
respond to a drug and selecting the drug and dose that is most appropriate for them.
In the context of pharmacogenomics, “phenotype” generally refers to efficacy or
toxicity and can be observed in multiple ways and defined qualitatively and
quantitatively. For example, efficacy may be defined more qualitatively as clinical
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response or quantitatively as a particular plasma drug level. Likewise, toxicity can be
defined in more qualitative clinical terms or it may be defined using a quantitative
measure such as platelet count.
The link between genotype and phenotype is often most obvious with severe
adverse drug reactions. One possible cause of an adverse drug reaction is genetic
variation in drug-metabolizing enzymes or transporters. For example, statin-induced
myopathy is 17x more likely to occur in individuals who are homozygous for a loss-offunction variant in the SLCO1B1 drug transporter gene. Another cause is genetic
variation in genes involved with immune response, such as the increased risk of severe
dermatologic reactions to abacavir in those with the HLA-B*5701 allele. A third cause is
variation in genes involved with the target or mechanism of a drug, such as increased risk
of warfarin-induced skin necrosis in individuals with genetic protein C deficiency.2
Efficacy or CYP enzyme activity are difficult phenotype to link directly to
genotype because they are also affected by environmental factors, demographic factors
such as age or sex, and interindividual variability in additional genes related to the drug’s
metabolism or mechanism of action. Because phenotypes such as efficacy or activity are
complex traits, the contribution of genetics is defined by the percentage of variation in
phenotype predicted. Genetic variants that explain 20 – 40% of phenotypic variance are
considered to have good discriminative power.2
A classification system is used in which predicted CYP enzyme activity
phenotype is described using the terms normal metabolizer, intermediate metabolizer,
poor metabolizer, and ultrarapid metabolizer.52
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Normal metabolizers (NMs) generally have a “normal” amount of enzyme
activity due to two copies of a fully functional allele. Intermediate metabolizers (IMs)
have reduced enzyme activity relative to normal metabolizers. This may be due to two
copies of a partially defective allele, a combination of a normal allele and a partially
defective or null allele, or a combination of a partially defective allele and null allele.
Individuals who are poor metabolizers (PMs) have no or very little detectable enzyme
activity due two copies of a non-functional allele. These non-functional alleles may be
due to gene deletions, insertions/deletions, splicing defects, or other polymorphisms that
inhibit gene translation or cause a loss of protein function. Ultrarapid metabolizers (UMs)
have one or more duplications of functional genes resulting in higher enzyme activity
levels than what is typically seen in NMs.
While this system has provided some consistency in prescribing a phenotype to an
individual from genetic data, there can still be large interindividual variability within
each phenotype class. Furthermore, there may be overlap between phenotype classes. For
example, an individual who is predicted to be a normal metabolizer may have lower
activity of the CYP of interest than someone who is predicted to be an intermediate
metabolizer. This may be due to confounding factors such as concomitant medication use
or age- or sex-related differences in enzyme expression.14 Another possibility is that the
NM individual may have an additional uncharacterized genetic polymorphism that results
in a loss or gain of enzyme activity.
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1.3 CYP2D6
1.3.1

Clinical relevance
CYP2D6 is responsible for the metabolism of 25% of all clinically used drugs

from a wide range of drug classes including antiarrhythmics, tricyclic antidepressants,
selective serotonin reuptake inhibitors, antipsychotics, beta-blockers, selective estrogen
receptor modulators, and opioid analgesics.14
To date, the CPIC has published guidelines that involve 12 different CYP2D6
substrates. Guidelines that focus solely on CYP2D6 are for codeine, anti-emetics
tropisetron and ondansetron, tricyclic antidepressants (TCAs) desipramine and
nortriptyline, and selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and
paroxetine. The guidelines for the TCAs amitriptyline, clomipramine, doxepin,
imipramine, and trimipramine also consider the diplotypes of both CYP2D6 and
CYP2C19 when making recommendations.
While the CPIC guidelines highlight drug/gene pairs with strong pharmacogenetic
associations, it is not always clear-cut. The utility of CYP2D6 pharmacogenetic testing
was questioned when two large clinical studies reported that CYP2D6 diplotype did not
predict clinical benefit in women with breast cancer being treated with tamoxifen. 53,54
This was controversial because previous studies had found an association between
CYP2D6 diplotype and plasma levels of endoxifen, an active metabolite formed by
CYP2D6. Adding to the controversy were issues with DNA quality and genotyping. A
major criticism of these studies was that the tumor sample DNA used for genotyping was
inappropriate and that results suggested undetected CYP2D6 deletion due to loss of
heterozygosity. 54,55 Another issue is that the authors only tested a limited number of
CYP2D6 variants and did not assess copy number variation to detect deletions or
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duplications. Despite these flaws, the studies have had widespread effects on clinical
practice. For example, the National Comprehensive Cancer Network references the
studies and states that they do not recommend CYP2D6 genotyping in patients treated
with tamoxifen, due to “limited and conflicting evidence.”56
1.3.1.1 Codeine
Variation in codeine metabolism represents a classic example of the clinical
relevance of CYP2D6 pharmacogenetics. Codeine is considered a prodrug; while codeine
has mild analgesic effects, its active metabolite, morphine has a 200-fold greater affinity
for the µ-opioid receptor. The formation of morphine is dependent upon the CYP2D6mediated O-demethylation of codeine. In poor metabolizers, the percentage of codeine
that is metabolized to morphine is lower than what is observed in normal metabolizers.
Studies have shown that poor metabolizers experience a decrease in analgesia as well as a
decreased incidence of side effects such as constipation. In ultrarapid metabolizers, a
higher percentage of codeine is metabolized into morphine than what is observed in
normal metabolizers. This represents the potential for more severe adverse effects as
increased morphine concentrations can result in respiratory depression or cardiac arrest.
The potential for serious adverse effects was fully realized in 2005 with the death
of a 13-day-old infant.57 His mother had been prescribed codeine for post-partum pain
and took it while breastfeeding, consistent with the American Academy of Pediatrics
listing codeine as being compatible with breastfeeding. Post-mortem analysis of the
infant found a morphine serum concentration of 70 mg/mL, much higher than the typical
value for breastfed infants of 0.2 – 2 ng/mL. Breastmilk that the mother had stored from
postpartum day 10 had a morphine concentration of 87 ng/mL. Typical values observed
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in breastmilk from women taking similar codeine doses range from 1.9 – 20.5 ng/mL.
The mother was genotyped for CYP2D6 and was found to be an ultrarapid metabolizer,
explaining the higher than normal concentration of morphine in her breastmilk.57
Following this case report, the FDA changed the codeine product label to include
a boxed warning cautioning against its use in children and information on the risks of
opioid toxicity in infants breastfed by mothers who are CYP2D6 ultrarapid metabolizers.
The label mentions that there is a pharmacogenetic test available but that they are not
routinely performed.58 The CPIC has since issued a guideline on codeine and CYP2D6
for use in the general population, recommending that codeine be avoided in ultrarapid
metabolizers and poor metabolizers in favor of alternate analgesics such as morphine or
non-opioid analgesics.59
1.3.1.2 Tricyclic antidepressants
Tricyclic antidepressants have largely fallen out of favor due to the high incidence
of side effects but still have roles in the treatment of refractory depression and pain.
Certain tricyclic antidepressants (amitriptyline, clomipramine, doxepin, imipramine, and
trimipramine) are demethylated by CYP2C19 to active metabolites. CYP2D6 then
hydroxylates them to less active metabolites. Desipramine and nortriptyline are not
metabolized by CYP2C19 but are hydroxylated by CYP2D6 to less active metabolites.
The CPIC guideline gives recommendations based on both CYP2C19 and CYP2D6
diplotype, but only the CYP2D6 recommendations will be discussed presently.
In CYP2D6 poor metabolizers, the metabolism of tricyclic antidepressants to less
active metabolites is reduced relative to normal metabolizers. The risk for adverse effects
is increased due to high plasma concentrations of more active metabolites of the drugs.
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The CPIC recommendation is to avoid the use of TCAs in poor metabolizers. If a TCA
must be used, the recommendation is to use a starting dose that is 50% lower than what is
recommended in the drug label and then to use therapeutic drug monitoring to guide dose
adjustments. In intermediate metabolizers, metabolism of TCAs is reduced, but not to the
extent that is observed in poor metabolizers. The CPIC recommends a 25% reduction in
starting dose and therapeutic drug monitoring. For ultrarapid metabolizers, the concern is
that TCAs will be metabolized at an increased rate, resulting in a loss of therapeutic
efficacy. In this case, the CPIC recommends avoiding TCAs or increasing the starting
dose and using therapeutic drug monitoring to guide dose adjustments.60
1.3.1.3 Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors have supplanted tricyclic antidepressants
as first-line therapy for the treatment of major depressive disorder. Like TCAs, SSRIs are
metabolized by CYP2C19 and CYP2D6. The efficacy and safety of SSRIs vary among
individuals; up to 50% will fail initial SSRI therapy and 25,000 patients visit emergency
departments every year due to SSRI-related adverse events. Some of this variability in
response is due to CYP2C19 and CYP2D6 pharmacogenetics.
Paroxetine and fluvoxamine are metabolized to inactive metabolites by CYP2D6.
Ultrarapid metabolizers are of the greatest concern, with multiple studies demonstrating
there is at ultrarapid metabolizers have low plasma paroxetine concentrations, putting
them at risk for treatment failure. The CPIC recommendation is that ultrarapid
metabolizers be treated with an alternative drug that is not metabolized by CYP2D6.
There is less evidence of treatment failure in ultrarapid metabolizers with fluvoxamine,
so the CPIC does not make a specific recommendation. Similarly, even though
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intermediate metabolizers would be expected to have decreased metabolism and thus
increased risk for adverse effects, there is not enough evidence to make recommendations
for adjustment to paroxetine or fluvoxamine therapy. Poor metabolizers have greater
exposure to paroxetine and fluvoxamine, potentially increasing the risk for adverse
effects. Per the FDA, the fluvoxamine drug label includes a precaution about use in
CYP2D6 poor metabolizers. Based on data from pharmacokinetic modeling, the CPIC
recommends a 50% reduction in starting dose for paroxetine and a 25-50% reduction for
fluvoxamine.61
1.3.1.4 Emerging areas
The CPIC ranks drug/gene pairs based on the level of supporting evidence in the
literature and prioritizes those with the highest level of evidence for new guidelines.
Opioid analgesics oxycodone and tramadol and selective estrogen receptor modulator
tamoxifen have an evidence rating of “A” and will likely be the next areas of focus for
guideline publication. Drugs with an evidence level of B are considered next. These are
primarily psychiatric drugs and include antipsychotics risperidone, brexpiprazole,
aripiprazole, pimozide, and mirtazapine, and antidepressants sertraline, venlafaxine, and
vortioxetine.62
The combination of dextromethorphan and quinidine is marketed for the treatment
of pseudobulbar affect, a condition characterized by involuntary laughing and/or crying.
Dextromethorphan, a CYP2D6 substrate, is responsible for the therapeutic effect and
quinidine, a CYP2D6 inhibitor, is used to increase dextromethorphan plasma levels.
Quinidine has no effect on dextromethorphan levels in CYP2D6 poor metabolizers so
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genotyping may spare patients from the potentially serious adverse effects associated
with quinidine, such as thrombocytopenia and torsades de pointes.63
1.3.2

CYP2D6 gene locus
The CYP2D6 gene is located in a segment on chromosome 22q13.2 that also

contains the pseudogenes CYP2D7 and CYP2D8.64 CYP2D6 itself is comprised of
approximately 5350 bp. All of the genes contain nine exons. Both pseudogenes have
similar nucleotide sequences to CYP2D6, with 92-97% homology across introns and
exons.65
CYP2D8 is downstream from CYP2D6 and does not encode a functional protein
product due to several insertions, deletions, and sequence variations that code for stop
codons. No mRNA has been observed in humans. The CYP2D7 pseudogene is
downstream from CYP2D8. It contains a nucleotide insertion in the first exon that results
frameshift responsible for a premature stop codon and thus a nonfunctional protein.66
Several intronic and exonic regions of CYP2D7 are identical to CYP2D6, as well as the
3’-ends and downstream repetitive regions. These similarities can result in gene
rearrangements that produce deletions, duplications, and hybrids of CYP2D6 and
CYP2D7.64
1.3.3

CYP2D6 nomenclature
The reference allele used to define the CYP2D6*1 sequence is GenBank entry

AY545216, submitted in 2005 by Gaedigk et al.67 This sequence supersedes GenBank
entry M33388, the first CYP2D6 sequence published in 1989 by Kimura et al.68 While
AY545216 corrects sequencing errors found in the previous reference sequence, M33388
is still used by convention to define nucleotide positions used in official allele definitions.
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Numbering starts with 1 at the M33388 sequence ATG start codon and has been
numbering guidelines have updated to reflect corrections to the original sequencing
errors.64
Currently, there are 113 primary star alleles defined for CYP2D6. Some of these
alleles have multiple suballeles. For example, CYP2D6*4 is defined by the presence of
1846G>A, a SNV that introduces an alternative splice site leading to nonfunctional
truncated CYP2D6 protein.69 There are currently fifteen *4 suballeles defined in the
nomenclature: CYP2D6*4A-*4P and CYP2D6*4X2, which represents a duplication of the
CYP2D6*4 allele. All of these alleles have the 1846G>A SNV in common but vary in
what additional SNVs they contain.70 The additional SNVs do not change the functional
consequence; every CYP2D6*4 suballele results in nonfunctional CYP2D6 protein.
Structural variants are not always obvious by their nomenclature. CYP2D6*5
represents the deletion of the CYP2D6 gene. Hybrid alleles, which are combinations of
CYP2D6 and CYP2D7, are given star designations, such as *13. Duplications are
described by listing the allele that is duplicated and the number of copies present on one
chromosome. The generic nomenclature for a duplicated allele has “xN” after a star
allele, e.g. *1xN. If there were 4 copies of the *1 allele present, it would be designated as
*1x4. Tandem alleles occur when two different alleles are found on the same
chromosome and are described as allele 1 + allele 2, e.g. *68 + *4.
1.3.4

Activity score
The activity score system was introduced by Gaedigk et al. in 2008 as a way to

simplify and standardize the clinical translation of CYP2D6 diplotype data.52 It has been
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adopted by the Clinical Pharmacogenomics Implementation Consortium (CPIC) as the
preferred method of translating diplotype into phenotype in CYP2D6 guidelines.64
One of the more common ways to translate drug-metabolizing enzyme diplotype
data into a phenotype prediction is with system that presents predicted phenotypes as
poor metabolizers, intermediate metabolizers, normal metabolizers, or ultrarapid
metabolizers. This method is challenging for CYP2D6 due to the large number of alleles
and potential complexity of particular allele combinations.
With the activity score system, a score of 0 is given to nonfunctional alleles, 0.5
to reduced function alleles, or 1 to functional alleles with activity comparable to the
CYP2D6*1 reference allele. Gene duplications are assigned a score that is a multiple of
single gene score (e.g. a duplication of the *41 reduced function allele (*41x2) would
have a score of 1 since *41 has an activity score of 0.5). Diplotype activity scores are
thus the sum of the individual allele scores that comprise the diplotype. Possible
diplotype scores are 0, 0.5, 1, 1.5, 2, and >2.64 The activity scores are then translated into
predicted phenotypes of poor metabolizers, intermediate metabolizers, normal
metabolizers, or ultrarapid metabolizers. Activity scores are qualitative and the scale does
not imply that an allele with a score of 0.5 has 50% of the activity of an allele with an
activity score of 1.
1.3.5

Relevant CYP2D6 alleles
CYP2D6*1 is the reference allele used to define a “wildtype” sequence that

encodes a CYP2D6 enzyme with normal activity. An allele is designated as CYP2D6*1 if
it does not include any of the other SNVs found in the alleles indexed by the CYP2D6
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allele nomenclature database.70 CYP2D6*1 is usually the most common allele found in
European and African populations.
CYP2D6*1xN refers to the duplication of the *1 allele, with N indicating how
many copies of CYP2D6*1 are present on a chromosome. Multiple copies of the *1 allele
results in an ultrarapid metabolizer phenotype.71
CYP2D6*2 is defined by the presence of two missense SNVs, 2850C>T and
4180G>C, that cause amino acid changes R296C and S486T. Functionally, CYP2D6*2
has slightly reduced activity compared to CYP2D6*1 but the difference is not considered
to be significant, resulting in CYP2D6*2 having an NM designation.72
CYP2D6*3 is defined by a deletion, 2549delA, that causes a frameshift mutation.
The frameshift causes premature truncation of the CYP2D6 protein, resulting in a
complete loss of function and a PM designation.73
CYP2D6*4 is defined by the presence of the intronic SNV 1846G>A, which
causes a disruption of the splice acceptor site in intron 3.74 CYP2D6*4 is nonfunctional
and designated as a PM.
CYP2D6*4xN refers to the duplication of the *4 alelle, with N indicating how
many copies of CYP2D6*4 are present on a chromosome. Since *4 is nonfunctional,
multiple copies do not result in increased CYP2D6 activity, so the allele is designated as
a PM.71
CYP2D6*4N+*4 consists of the hybrid allele *4N in tandem with *4N. Because
both *4N and *4 are nonfunctional, it is a PM allele.75
CYP2D6*5 is the total deletion of the CYP2D6 gene caused by homologous
recombination of the rep 7 and rep 6 regions and looping out of the gene.76 Since no
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functional protein is produced from a deleted gene, CYP2D6*5 has the designation of
PM. The current PGRNSeq platform is not designed to detect the CYP2D6*5 allele but a
novel bioinformatics tool, Stargazer (discussed further in Chapter 2), has been developed
to determine CYP2D6 copy number using PGRNSeq read depth data.
CYP2D6*6 is defined by a deletion of a single nucleotide in exon 3, 1707delT,
that causes a frameshift. The frameshift leads to the generation of a premature stop codon
located one codon after the deletion. The truncated CYP2D6 protein is nonfunctional and
results in a PM designation.77
CYP2D6*9 is defined by the deletion of three nucleotides, 2615_2617delAAG,
resulting in the deletion of a single amino acid, K281del. The CYP2D6*9 allele confers
reduced function and in vitro studies suggest that this is due to reduced expression rather
than changes in catalytic activity.78
CYP2D6*10 is defined by the SNVs 100C>T, 1661G>C, and 4180G>C and has
reduced function. The 100C>T variant causes a deleterious protein change, P24S, that has
been associated with reduced CYP2D6 expression and catalytic activity. 79
CYP2D6*17 is defined by the presence of four SNVS, 1023C>T, 1661G>C,
2850C>T, and 4180G>C. CYP2D6*17 is a reduced function allele. This effect appears to
be due to substrate-specific changes in Km. 80
CYP2D6*20 contains an insertion, 1973_1974insG, that causes a frameshift,
generating a premature stop codon. The truncated CYP2D6 protein is nonfunctional and
results in a PM designation.81
CYP2D6*29 is defined by the presence of the SNVs 1659G>A and 3183G>A,
which cause protein changes V136I and V338M. The CYP2D6*29 allele encodes an
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enzyme with reduced function, possibly due to changes in Km that are substratespecific.82
CYP2D6*33 is defined by the presence of a single SNV, 2483G>T, which causes
the protein change A237S. CYP2D6*33 has normal activity.70
CYP2D6*35 is defined by the presence of SNVs 31G>A, 2850C>T, and
4180G>C. The 31G>A SNV results in the protein change V11M. CYP2D6*35 confers
normal protein activity.70
CYP2D6*36+*10 is a hybrid tandem allele, meaning that two CYP2D6 alleles,
*36 and *10, exist together on the same chromosome. *36 is nonfunctional but *10 has
intermediate activity, so the overall allele is designated as an IM.71
CYP2D6*39 is defined by the presence of 1661G>C and 4180G>C in the absence
of 2850C>T. It has normal activity.70
CYP2D6*41 is defined by the presence of intronic SNV 2988G>A, which causes
a splicing defect, in combination with 1661G>C, 2850C>T, and 4180G>C. CYP2D6*41
is a reduced function allele. The hypothesized mechanism is reduced protein expression
secondary to the splicing defect.83
CYP2D6*41x2 refers to the duplication of the *4 alelle, with two copies of *41 on
the same chromosome. Since *41 has reduced function, two copies result in roughly
normal CYP2D6 activity, designating it as an NM.71
CYP2D6*43 is defined by the presence of a single SNV, 77G>A, which results in
the protein change R26H. This allele confers normal function.70
CYP2D6*59 is defined by the presence of the SNVs 2291G>A and 2939G>A in
combination with 1661G>C, 2850C>T, and 4180G>C. CYP2D6*59 is a reduced function
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allele. Of the SNVs unique to CYP2D6*59, 2291G>A is found in intron 4 and it is not
clear if it contributes to the intermediate metabolizer phenotype. The second SNV,
2939G>A, causes a synonymous change in exon 6. The mechanism has not been fully
elucidated, but it is hypothesized that the 2939G>A SNV may cause splicing defects or
that it may cause changes in secondary mRNA structure.84
CYP2D6*68+*4 is a hybrid tandem allele, meaning that two CYP2D6 alleles, *68
and *4, exist together on the same chromosome. Both alleles are nonfunctional, so the
overall allele is designated as a PM.71
1.3.6

Other sources of CYP2D6 variation

1.3.6.1 Ethnicity
CYP2D6 allele frequencies vary across world populations. Europeans have a
relatively high frequency of individuals with a poor metabolizer phenotype. This is
largely due to the loss of function *4 occurring at a frequency of 18% in people of
European descent. It is lowest in East Asians with a frequency of 0.6%
Intermediate metabolizer phenotypes are most common in East Asian, African, and
Middle Eastern populations. The intermediate function allele, *10, is most common in
East Asians and occurs at a frequency of 45%. The *17 and *29 alleles are most common
in African populations and occur at frequencies of 20% and 9%, respectively. Hybrid
genes appear to occur more often in Africans, as well. The *41 allele is most common in
Middle Eastern populations, occurring at a frequency of 20%. Ultrarapid metabolizer
phenotypes are found most often in Oceanian and Middle Eastern populations due to the
high frequency of alleles containing gene duplications.85-87
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1.3.6.2 Age and sex
Data on the effect of age and sex on CYP2D6 activity are conflicting and vary
depending on the probe substrate used.88
1.3.6.3 Drug-drug interactions
CYP2D6 is subject to inhibition by a variety of drugs, potentially resulting in
drug-drug interactions. Strong inhibitors, which increase the AUC of a second CYP2D6metabolized substrate by ≥5-fold, include bupropion, fluoxetine, paroxetine, quinidine,
and terbinafine. Moderate inhibitors, which increase the AUC of a second substrate by ≥2
to <5-fold, include cimetidine, cinacalcet, duloxetine, fluvoxamine, and mirabegron.89
Paroxetine and cimetidine are mechanism-based inhibitors and the others are reversible.71
1.3.6.4 Liver disease
The effects of liver disease on CYP2D6 activity vary with etiology. In general,
CYP2D6 is not as sensitive to liver disease as other CYPs such as CYP1A2, 2C19, and
3A4/5. Patients with chronic hepatitis C have been reported to have 2.6x less CYP2D6
activity versus those without hepatitis C. Anti-CYP2D6 antibodies are present in those
with autoimmune hepatitis and have been identified in some patients with chronic
hepatitis C. In one study, patients who produced these antibodies had CYP2D6 activity
levels 80% lower than those who did not produce antibodies.71
1.3.6.5 Cytochrome P450 Oxidoreductase
Cytochrome P450 oxidoreductase (POR) transfers electrons from NADPH to
CYP enzymes, a rate-limiting step in CYP-mediated drug metabolism. The POR gene is
polymorphic and certain variants cause a syndrome consisting of skeletal dysplasia,
impaired steroidogenesis, and genital ambiguity. Other variants do not cause a disease
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phenotype but have been associated with decreased CYP enzyme function. A POR
variant may only affect the activity of certain CYP enzymes and the effect may be
substrate-specific. Because POR is required for CYP enzyme function, genetic variation
in the POR gene may explain some of the variability in CYP activity not explained by
CYP genetics. A study examining the effects of various recombinant POR variants on
CYP2D6 activity found that POR with common variant A503V decreased CYP2D6
activity by 40-50% when using dextromethorphan and bufurolol as probes.90
1.3.6.6 Aldo-keto reductase 1D1
Aldo-keto reductase 1D1 (AKR1D1) is involved in the bile acid homeostasis and
is hypothesized to regulate CYPs through activation of nuclear receptors that
transcriptionally regulate CYP expression. Bile acids are ligands of nuclear receptors
PXR and CAR, which induce the transcription of CYP3A4, CYP2C9, and CYP2C19.
Since CYP2D6 is generally considered to be non-inducible, this mechanism of CYP
regulation should not affect CYP2D6 activity. However, it is possible that there are
additional pathways that have not yet been described.91
1.3.7

CYP2D6 genotyping methods
CYP2D6 is technically difficult to sequence due to a large number of variants,

copy number variation, the presence of hybrid and tandem alleles, repeat regions, and
high sequence homology with the CYP2D7 pseudogene.92
Targeted genotyping is a method used to test for the presence of specific variants
using methods such as TaqMan PCR assays. This method can be problematic for
CYP2D6 because rare variants that alter enzyme activity will not be detected, nor will
more common variants that were not included on the genotyping panel. When no variants
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are detected, allele assignment “defaults” to CYP2D6*1 and individuals may erroneously
be predicted to be normal metabolizers. Also, targeted genotyping will not provide
information on copy number variation unless it is specifically assessed using quantitative
real-time PCR. Results of this type of copy number variation assay may be ambiguous
since it only reports a generic duplication signal. In diplotypes such as *1/*4, either allele
may be duplicated with different effects on enzyme function. CYP2D6*1 is a functional
allele, so a duplication would cause increased function; on the other hand, CYP2D6*4 is
non-functional so a duplication would not change CYP2D6 phenotype.92
Sequencing allows for the detection of uncommon or rare variants but has its own
unique technological challenges. Short-read sequencing allows for read lengths of up to
300 bp and is the most common sequencing method used commercially. Repetitive
regions and pseudogenes are issues for short-read sequencing because the reads may not
be long enough to distinguish between regions of the gene locus. Long-red sequencing
platforms currently have average read lengths of approximately 10 kb, offering a large
improvement over short-read sequencing.92
Targeted exome sequencing of selected pharmacogenes, such as with the PGRNSeq
platform, offers an approach that can be conducted for less time and money than whole
genome or exome sequencing. By focusing on selected genes, targets can be sequenced
with deep coverage at relatively high throughput.93 Furthermore, read depth data can be
used to assess CYP2D6 copy number and for the presence complicated structures such as
hybrid genes.
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1.4 Specific aims
Aim 1: Assign CYP2D6 haplotypes to human liver microsome samples from a
panel of livers and determine expected CYP2D6 activity scores. Use sequencing data
provided by the PGRNSeq platform to assign common CYP2D6 haplotypes and identify
any novel or rare coding variants.
Aim 2: Perform an in vitro probe study to determine CYP2D6 activity in
human liver microsome samples. Identify SNVs that may explain phenotypic
outliers. Use CYP2D6 probe drugs dextromethorphan and metoprolol in human liver
microsome (HLM) incubations to estimate CYP2D6 activity.
Aim 3: Incorporate Stargazer data on structural and copy number variation to
evaluate the change in the percent variation in CYP2D6 activity predicted by
activity score. Reassign diplotypes using Stargazer data and determine if correlation of
CYP2D6 activity with activity score is improved.
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2 A multifactorial cytochrome P450 2D6 genotype-phenotype
prediction model to improve precision of clinical
pharmacogenomic tests
2.1 Introduction
Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of up to 25% of
medications from widely-used classes such as beta-blockers, antiarrhythmics, selective
serotonin reuptake inhibitors, tricyclic antidepressants, antipsychotics, and opioid
analgesics.94 A high degree of interindividual variability in CYP2D6 activity has been
observed and much of this can be attributed to variation in the highly polymorphic
CYP2D6 gene.95
The combination of a wide range of clinically-relevant substrates and a wellstudied link between genetics and activity has made CYP2D6 a logical candidate for
clinical pharmacogenetic testing. Currently, information on CYP2D6 pharmacogenetics is
included in the labeling for 52 FDA-approved drugs.96 To provide guidance on
implementation of pharmacogenomics testing in the clinic, groups such as the Clinical
Pharmacogenetics Implementation Consortium (CPIC) have published guidelines for 12
gene-drug combinations from 4 therapeutic classes that are metabolized by CYP2D6.97
The CYP2D6 gene is notoriously difficult to interrogate due to challenges
imposed by the complexity of the CYP2D6 gene locus. To date, over 100 CYP2D6 alleles
have been defined, many of which are comprised of multiple variants. Techniques such
as targeted genotyping are of limited utility for CYP2D6 because logistics limit the
number of many possible variants to test. Such strategies may miss clinically relevant
variants that were present in an individual but not included in the platform. Because of
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the way many CYP2D6 haplotypes build on a *1 or *2-like “background,” an individual
may have a deleterious variant, but if it is not tested for, their diplotype will default to *1
or *2, predicting normal CYP2D6 activity when it is actually reduced or absent. 64,92 This
is particularly problematic in diverse populations, where data is lacked about relevant
functional variation; if functional variants are missed in these populations, a default *1 or
*2 variant would incorrectly assign individual phenotypes. 85,92
In addition to sequence variation, structural variation is an important
consideration in assigning CYP2D6 diplotypes. The CYP2D6 gene locus has a high
degree of structural variation that results in not only copy number variation (CNV) like
gene deletions and duplications, but also gene rearrangements between CYP2D6 and the
adjacent pseudogene CYP2D7 with high homology to CYP2D6, which lead to CYP2D6CYP2D7 hybrids. Structural variation is not uncommon: the CYP2D6*5 allele, a deletion
of the CYP2D6 gene, occurs at a frequency of 2 – 6% worldwide, while duplications that
cause increased function, such as CYP2D6*1xN, occur at a frequency of 2 – 12%.92 If
CYP2D6 pharmacogenetic tests do not assess structural variation, a relatively large
number of people may be assigned an incorrect diplotype.
The goal of this study was to compare the predictive power of CYP2D6 diplotype
and activity score assignments based on single nucleotide variation (SNV) and small
insertion or deletion (indel) data alone and assignments using Stargazer, a software tool
for assigning alleles from next-generation sequencing data that combines SNV/indel calls
with structural variation data to improve the predictive model. We assessed CYP2D6
activity in a panel of 309 human livers using CYP2D6 probe substrates, metoprolol and
dextromethorphan. Metoprolol is metabolized to α-hydroxymetoprolol and
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dextromethorphan is metabolized to dextrorphan via CYP2D6. We then used PGRNSeq,
a next generation sequencing platform, to assign CYP2D6 diplotypes; we compared
assignments from SNV data alone and incorporation of structural variation identified
from Stargazer. Finally, we compared the amount of variation in CYP2D6 activity
predicted by activity score assignments from the two methods.

2.2 Materials and methods
2.2.1

Chemicals and reagents
Dextromethorphan, metoprolol tartrate, NADPH, potassium phosphate, EDTA,

and acetonitrile were purchased from Sigma-Aldrich (St Louis, MO, USA). Dextrorphand3 was purchased from Cerilliant (Round Rock, TX, USA). Carvedilol-d3 was purchased
from C/D/N Isotopes (Pointe-Claire, QC, CA).
2.2.2

Human liver samples

2.2.2.1 Human liver microsomes, total protein quantitation, cytochrome P450
oxidoreductase protein quantitation, genomic DNA extraction
Human liver samples (n = 347) were obtained from the University of Washington
Human Liver Bank (n = 65) and the St. Jude Liver Resource at St. Jude Children’s
Research Hospital (n = 282) as described previously. HLM preparation and total protein
quantitation were previously described.98 A subset of 309 HLMs were used in this study,
with 47 from the University of Washington and 262 from St. Jude liver banks.
2.2.2.2 CYP2D6 and POR protein quantitation and CYP2D6, POR, and AKR1D1
mRNA quantitation
Microsomal CYP2D6 and POR protein content was quantitated using a surrogate
peptide-based LC-MS/MS method that has been previously described. 98,99 Methods for
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RNA isolation, TruSeq stranded mRNA preparation, read processing, and analysis have
also been previously described.100
2.2.2.3 DNA isolation, CYP2D6 sequencing, and CYP2D6 allele and activity score
assignment
The PGRNSeq platform was used to identify CYP2D6 genomic variation. All
CYP2D6 exons as well as the regions 2 kb upstream and 1 kb downstream were
sequenced using the PGRNseq platform, as previously described.93 Allele and subsequent
star-allele diplotype assignments were first made manually using SNV and indel data
only and based on criteria from the Pharmacogene Variation Consortium
(https://www.pharmvar.org/gene/CYP2D6). The Stargazer algorithm (paper submitted)
was then used to detect structural variation in the CYP2D6 gene in PGRNseq sequencing
data and the star-allele diplotype assignments determined manually were corrected
accordingly. Activity scores were assigned to each allele based on CPIC criteria.101
2.2.2.4 Measurement of CYP2D6 metabolite formation rate in HLMs
HLM incubations were conducted using a dextromethorphan concentration of 1.5
µM and a metoprolol concentration of 4 µM. Optimization experiments confirmed that
these concentrations were in the linear range of metabolite formation; additional
optimization conditions confirmed that incubation time and total HLM protein content
were also within linear conditions (data not shown). Incubations were performed in
triplicate using 20 µg of total HLM protein per well diluted in pH 7.4 100 mM potassium
phosphate and 1 mM EDTA buffer. HLMs were pre-incubated with substrate for 5 min at
37°C. NADPH (final concentration 1 mM) was added to start the reaction and samples
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were incubated for 20 min (metoprolol) and 30 min (dextromethorphan) at 37°C.
Reactions were terminated by the addition of ice-cold acetonitrile.
2.2.2.5 Metabolite and parent drug quantitation
For metoprolol and α-hydroxymetoprolol, calibration standards were prepared
over the range of 0.003 to 0.176 µM; carvedilol-d4 (1 ng/µl) was used as an internal
standard. Ions m/z 284.1 and 411.1 were monitored for α-hydroxyl-metoprolol and
carvedilol-d4, respectively. The mobile phase was 10mM ammonium formate, pH 4, in
water (A) and acetonitrile (B) using the following gradient: 0 min 15% B, 3.5 min 60%B,
4.5 min 90%B, 5 min 90%B, 5.1 min 15%B, and 9.5 min 15%B.
For dextromethorphan and dextrorphan, calibration standards were prepared over
the range of 0.004 to 1 µM; dextrorphan-d3 (0.5 ng/µl) was used as an internal standard.
Ions m/z 258.1 and 261.1 were monitored for dextrorphan and dextrorphan-d3,
respectively. The mobile phase was 0.1% formic acid in water (A) and acetonitrile (B)
using the following gradient: 0 min 20% B, 1 min 20% B, 5 min 40% B, 6 min 20% B,
and 9 min 20% B.
Quantitation of dextromethorphan dextrorphan, metoprolol, and αhydroxymetoprolol was performed on an Agilent Technologies G1956B mass
spectrometer coupled to an Agilent 1200 series HPLC using a Zorbax SB-C18 2.1 mm x
150 mm x 5 µm column (Agilent Technologies, Santa Clara, CA). For dextrorphan, the
column was maintained at 30°C with a flow rate of 0.3 ml/min. For αhydroxymetoprolol, the column was maintained at 35°C with a flow rate of 0.25 ml/min.
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2.2.2.6 Statistical analysis
Samples were included for statistical analysis if both PGRNSeq and activity data
for at least one probe substrate were available (n =309). All analyses were performed
using RStudio 1.0.143 (Boston, MA). In all analyses, liver collection site was included as
a covariate due to significant differences in mean enzyme activity between the sites as
well as differences in POR mRNA and protein content and AKR1D1 mRNA content.
Pairwise associations between donor demographics (e.g. sex, ethnicity, age), liver
microsomal CYP2D6 and POR protein content, liver microsomal CYP2D6, POR, and
AKR1D1 mRNA content, and liver microsomal CYP2D6 activity (dextrorphan and αhydroxymetoprolol formation rate) were tested with linear regression using robust
standard errors. This approach was also used to test the association between activity score
and CYP2D6 activity. A multivariate linear regression model with robust standard errors
was used to assess the contribution of selected predictors to the variability observed in
CYP2D6 activity.

2.3 Results
2.3.1

Liver donor demographics
Liver donor demographics (n = 309) are presented in Table 1. Donors ranged

from 0 to 87 years old, with an average age of 39.6 years. A majority of the donors were
male (58.3%) and almost all were of European descent (95.5%). Liver tissue was
collected from donors at two sites: the University of Washington in Seattle, WA (n = 47)
and St. Jude Children’s Research Hospital in Memphis, TN (n = 262). Data on liver
pathology and/or disease were not collected for all donors; similarly, medication lists are
missing for some donors and possibly incomplete for others.
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2.3.2

Effects of CYP2D6 mRNA and protein content on activity
The rates of α-hydroxymetoprolol and dextrorphan formation, used as a measure

of CYP2D6 activity, were both significantly correlated with CYP2D6 mRNA content
(Figures 3A and 3B) and CYP2D6 protein content (Figures 4A and 4B). For association
between metabolite formation rates and CYP2D6 mRNA content, R2 values were 0.231
and 0.254 for α-hydroxymetoprolol and dextrorphan formation rates, respectively.
CYP2D6 protein content had a much stronger association with CYP2D6 activity, as
reflected in higher R2 values of 0.643for α-hydroxymetoprolol formation rate and
0.751for dextrorphan formation rate. It should be noted that protein data were only
available for 98 of the 309 samples analyzed, 10 of which were below the lower level of
quantitation. With collection site included as a covariate, CYP2D6 mRNA content was
not a significant predictor of CYP2D6 protein content.
2.3.3

CYP2D6 allele and diplotype frequencies in the liver bank samples
We identified 23 alleles in the liver bank samples using the Stargzer algorithm

(Table 2) and 69 unique diplotypes (Table 3). Allele frequencies reflect the
predominantly European descent of the liver bank samples. The three most common
alleles were CYP2D6*1 (32%), CYP2D6*2 (14.7%), and CYP2D6*4 (13.8%), which is
consistent with published reports for populations of European descent.85
To summarize, a total of seven different alleles, including CYP2D6*1 and
CYP2D6*2, were identified that confer normal enzyme function and a normal
metabolizer (NM) phenotype (activity score of 1). The seven NM alleles occurred at an
aggregate frequency of 54.2%. Six alleles were identified with reduced enzyme function
and an intermediate metabolizer (IM) phenotype (activity score of 0.5). The most
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common IM allele was CYP2D6*41 (11.2%), a splice variant allele found most
commonly in European populations. The IM alleles occurred at an aggregate frequency
of 18.9%. Seven loss of function alleles were identified conferring a poor metabolizer
(PM) phenotype (activity score of 0), occurring at an aggregate frequency of 25.7%. The
most common PM allele was CYP2D6*4 (13.8%). Two alleles associated with the
ultrarapid metabolizer (UM) phenotype (activity score of 2) were identified,
CYP2D6*1x2 (0.5%) and CYP2D6*2x2 (0.6%).
2.3.4

Structural variation data is critical for correct diplotype assignment
A total of 16 unique alleles were identified from SNV/indel data alone. The

inclusion of data on structural variation allowed for the identification of 7 additional
alleles with gene deletions, gene duplications, and hybrid tandem gene arrangements,
bringing the total to 23 unique alleles (Table 2).
Activity scores were assigned from diplotypes identified from SNV/indel data
alone (16 alleles) and from diplotypes identified with the inclusion of structural variation
data (23 alleles). When the samples were analyzed incorporating structural variation data,
67 samples (22%) were incorrectly assigned with SNV/indel data alone. Importantly,
inclusion of structural variation data changed the predicted activity score for 26 of those
samples, representing approximately 8% of the liver bank donors. Figure 1 describes the
diplotypes of the 67 samples with structural variation alleles that were identified with
Stargazer as well as changes in activity score resulting from changes in predicted activity
score.
CYP2D6*5, a complete gene deletion, was identified in 23 samples, occurring at
an allele frequency of 3.7%. The importance of including the *5 allele is evident as the
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corrected diplotype calls decreased the activity score of 18 samples in this sample set
(5.8%). The remaining five samples already had activity scores of 0 and thus could not be
decreased further.
A total of 8 duplicated alleles in the form of CYP2D6*xN were identified,
consisting of CYP2D6*1x2, CYP2D6*2x2, and CYP2D6*41x2. As these are all
duplications of functional alleles, they resulted in activity score increases for all of the
samples they were identified in.
Structural data were also used to detect the hybrid tandem alleles CYP2D6*4N+*
4, CYP2D6*68+*4, and CYP2D6*36+*10. Inclusion of hybrid tandem alleles did not
result in any activity score changes in our sample set. CYP2D6*68+*4 is a nonfunctional allele identified in samples previously designated as *4 with SNV/indel data
alone, and were already assigned an activity score of 0. CYP2D6*36+*10 was identified
in samples previously designated *10, which both have an activity score of 0.5. Published
data suggest that there is no significant difference in enzyme activity conferred by
CYP2D6*36+*10 and *10 alone102; thus, the activity score did not change from 0.5.
The inclusion of structural data in CYP2D6 significantly improved the predictive
value of the activity score assignments for both probe substrates, metoprolol and
dextromethorphan (Figure 2; Table 4). Using SNV/indel data alone, activity score
predicted 31.5% and 36.4% of the variability in CYP2D6 activity when using metoprolol
and dextromethorphan as probes, respectively (Table 4A). With structural variation data
included from Stargazer, these numbers increased to 36.6% and 40.7% (Table 4B).
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2.3.5

Liver collection site, POR protein content, and AKR1D1 mRNA content
contribute to variability in CYP2D6 activity
Liver collection site was highly predictive of CYP2D6 activity, consistent with

our collaborators reports from these liver bank samples; therefore, collection site was
included in all analyses as a covariate. 98,100 POR protein content, but not mRNA content,
was significantly associated with metabolite formation rate for both α-hydroxymetoprolol
(R2 = 0.198, p < 0.001) and dextrorphan formation rate (R2 = 0.219, p < 0.001) (Figure
5). AKR1D1 mRNA content was also associated with CYP2D6 activity for both αhydroxymetoprolol (R2 = 0.16, p < 0.001) and dextrorphan formation rate (R2 = 0.208, p
< 0.001) (Figure 6).
2.3.6

Multivariate regression analysis of CYP2D6 activity
A multivariate linear regression using robust standard errors was performed to

determine which variables, in addition to activity score, explain some of the variability in
CYP2D6 activity (Table 5). Donor age and sex were not included in the model due to a
lack of significance in primary analysis, which is consistent with the literature.88 While
ethnicity is known to make a large contribution to variation in CYP2D6 activity, we did
not include it as a covariate in our model because the liver donors were almost entirely of
European descent. We also excluded liver disease and concomitant CYP2D6 inhibitors
because the data were incomplete for the majority of donors.
The R2 for α-hydroxymetoprolol formation rate was 0.471, an improvement over
the value of 0.364 obtained when just activity score and collection site were used as
predictors. The R2 for dextrorphan formation rate was 0.505, also an improvement over
the value of 0.407 obtained when just activity score and collection site were used as
predictors. The covariates that contributed to these increases in R2 were POR protein
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content and AKR1D1 mRNA content. Similar to what was observed in the model that
included just activity score and collection site, activity scores of 2 and 3 were not
significant predictors of CYP2D6 activity.

2.4 Discussion
We found that inclusion of structural variation data is essential to correctly
assigning CYP2D6 activity scores and these data are more predictive of CYP2D6 activity
than activity scores assigned based on SNV/indel data alone. Accurate identification of
gene deletions, gene duplications, and hybrid alleles will maximize the clinical utility of
CYP2D6 pharmacogenetic tests. We also found that POR protein content is correlated
with CYP2D6 activity. As POR is a polymorphic gene, inclusion of POR
pharmacogenetic data in the clinical setting may further improve CYP2D6 phenotype
prediction.
When diplotypes were assigned based on SNV/indel data alone, resultant activity
scores explained about 31% of the variation in CYP2D6 activity when metoprolol was
used as a probe and 36% of the variation when dextromethorphan was used. When
diplotypes were reassigned based on the Stargazer algorithm that utilizes both SNV/indel
and structural variation data, this number increased to approximately 36% for metoprolol
and 41% for dextromethorphan. The diplotypes of 67 samples were reassigned,
representing over 20% of the samples tested. Importantly, the activity score changed for
26 samples, representing approximately 8% of the samples tested. The samples that had
incorrect activity scores contained alleles that contribute to “extreme” phenotypes: the
whole-gene deletion CYP2D6*5 or duplications of functional alleles CYP2D6*1, or *2.
The hybrid alleles *4N, *36, and *68 are nonfunctional and thus did not affect activity
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score assignments when in tandem arrangements with alleles identified via SNV/indel
analysis (*4 or *10). These tandem hybrid alleles are still important to identify, though,
since their presence is informative when resolving potentially ambiguous diplotypes. For
example, many commercially available tests would detect a duplication in an individual
with a *1/*4N + *4 diplotype but would be unable to determine if the duplication is on a
*1 or *4 allele.
Due to the lack of ethnic diversity in the liver bank donors, we were unable to
assess for differences in CYP2D6 activity that may be attributable to ethnicity. Though
very few liver donors were of non-European descent, however, their presence is reflected
in some of the more uncommon alleles. The *17 allele occurs at a frequency <1% in
European populations and an average of 18.2% in African Americans.85 In this study, the
allele was present in four donors, two of them of known African descent. An AfricanAmerican donor also contributed the single *29 allele, which occurs at frequencies of
<1% in those of European descent and 6.5% in those of African descent.85 In East Asian
populations, the *10 allele is very common, occurring at an average frequency of 42.6%.
The CYP2D6*10 allele is also found in tandem with the hybrid CYP2D6*36 allele as
CYP2D6*36+*10, found most frequently in East Asian populations at an average
frequency of 26.4%.85,103 These high frequency alleles were observed in the
CYP2D6*10/*36+*10 diplotype of the only Asian donor included in this study.
CYP2D6 activity was significantly correlated with both CYP2D6 mRNA and
protein contents. The correlation with CYP2D6 mRNA was weaker, suggesting that
mRNA content does not explain very much of the variability in CYP2D6 activity. The
correlation with protein, on the other hand, was much stronger, which is unsurprising
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since the CYP2D6 enzyme content is more proximal to metabolite formation rate than
mRNA in the regulatory scheme. The correlation between CYP2D6 mRNA and protein
was not significant, which fits a general, genome wide trend of low mRNA-protein
correlations.104
The correlation between CYP2D6 activity and POR protein content was
significant for both substrates. Further investigation into POR diplotype for each sample
would be worthwhile. Because POR is required for CYP enzyme function, genetic
variation in the POR gene may explain some of the variability in CYP activity not
explained by CYP genetics. Previous data supports a possible link between POR and
CYP2D6. A study examining the effects of various recombinant POR variants on
CYP2D6 activity found that the common POR variant A503V decreased CYP2D6
activity by 40-50% when using dextromethorphan and bufurolol as probes.90 Thus, POR
genotyping may provide additional information that can be used with CYP2D6 diplotype
data in a clinical setting to improve CYP2D6 phenotype predictions.
AKR1D1 mRNA content was very weakly correlated with CYP2D6 activity.
AKR1D1 protein content data were not available for comparison. AKR1D1 is involved in
bile acid homeostasis and is hypothesized to regulate CYPs through activation of nuclear
receptors that transcriptionally regulate CYP expression. Bile acids are ligands of nuclear
receptors PXR and CAR, which induce the transcription of CYP3A4, CYP2C9, and
CYP2C19. Since CYP2D6 is generally considered to be non-inducible, this mechanism of
CYP regulation should not affect CYP2D6 activity. It is possible, however, that there are
additional regulatory pathways that have not yet been described.91 Interestingly, AKR1D1
mRNA remained a significant predictor for both substrates, suggesting that AKR1D1
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might affect CYP2D6 through the hypothesized mechanism or through a mechanism that
has not yet been described.
The liver procurement site explained a relatively large amount of variability in CYP2D6
activity (7.8% for metoprolol, 12.8% for dextromethorphan) and was a significant
predictor for both probe substrates. Other groups have noted similar differences when
using the liver bank to study CYP2A6 and CYP2C19. 98,100 Factors such as liver tissue
collection method and storage conditions are some of the many variables that may have
contributed to the site difference.
A multivariate linear regression model was used to assess the combined
contributions of activity score, POR protein content, AKR1D1 mRNA content, and liver
procurement site to variability in CYP2D6 activity. All of the covariates were significant
predictors of CYP2D6 activity except for activity scores 2 and 3. Compared to the other
activity score categories, there was a higher degree of variability in CYP2D6 activity for
activity scores 2 and 3. Also, the metabolite formation rates for samples with an activity
score of 3 were lower than expected and we are unable to explain this with the PGRNSeq
data. Some of this may have been due to the small number of samples (n = 3) with an
activity score of 3. These findings could also be due to genetic variation that has yet to be
described, either in the CYP2D6 gene (although that is less likely with the methodology
employed), regulatory regions, genes related to CYP2D6 function such as POR, or due to
co-administration of CYP2D6 inhibitors not recorded in donor medication lists.
Together, data on CYP2D6 activity score, POR protein content, AKR1D1 mRNA
content, and liver procurement site explained 47% and 51% of the variability in CYP2D6
activity when metoprolol and dextromethorphan were used as probes, respectively.
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Limitations of this study include small sample sizes in the activity score 2.5 (n=2)
and 3 (n=3) categories and a relatively large amount of variation in the activity score 2
and 3 categories. One sample in particular, genotyped as a *1/*1x2 and assigned an
activity score of 3, had very low CYP2D6 activity, consistent for both probe drugs. It’s
unclear if this is due to unidentified genetic variation in CYP2D6, post-transcriptional
regulation, unrecorded use of drugs that inhibit CYP2D6, or issues such as low HLM
quality.
Most currently available CYP2D6 pharmacogenetic tests are designed to detect a
limited selection of alleles with SNVs and indels, the whole-gene deletion CYP2D6*5,
and nonspecific duplication signals (*xN). Our approach of using Stargazer to analyze
targeted exome sequencing data offers a solution to many of the problems with current
tests. First, we can detect uncommon and rare alleles not included on targeted genotyping
panels, solving the problem of defaulting to a call of CYP2D6*1 or CYP2D6*2 when a
functional allele is present but not tested for. Second, our approach allows for
identification of specific duplicated alleles rather than a potentially ambiguous
nonspecific duplication signal. Third, the ability to identify hybrid genes in tandem
arrangements with CYP2D6 solves the problem of incorrect duplication calls when using
real-time PCR CYP2D6 copy number assays. Furthermore, identification of hybrid alleles
that do not occur in tandem with CYP2D6 is an improvement over PCR-based
genotyping methods that may over-amplify the non-hybrid allele, making the sample
appear to be homozygous for the non-hybrid.75
For a gene as complicated as CYP2D6, analysis of SNVs and indels alone is not
sufficient for making accurate allele calls. If we are to strive for precision, structural
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variation in the CYP2D6 gene must also be analyzed beyond CYP2D6*5 and nonspecific
duplication signals.
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2.5 Tables
2.5.1 Table 1. Liver donor demographics (n = 309)
Age
Mean ± SD

39.6 ± 22.4

Range

0 - 87

Sex
Male

180 (58.3%)

Female

124 (40.1%)

Unknown

5 (1.6%)

Ethnic background
European

295 (95.5%)

African

9 (2.9%)

Asian

1 (0.3%)

Hispanic

1 (0.3%)

Unknown

3 (1.0%)

Liver disease
No / not recorded

256 (82.8%)

Yes

53 (17.2%)
Fatty liver

25 (47.2%)

Cancer

7 (13.2%)

Fibrosis

5 (9.4%)

Acute injury

4 (7.5%)

Cirrhosis

4 (7.5%)

Hepatitis

4 (7.5%)

Biliary atresia

4 (7.5%)

CYP2D6 inhibitor
No / not recorded

295 (95.5%)

Yes

14 (26.4%)
Cimetidine

12 (85.7%)

Amiodarone

1 (7.1%)

Fluoxetine

1 (7.1%)
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2.5.2
Allele

Table 2. CYP2D6 alleles (n = 618) identified in liver bank samples
n (%)

Nucleotide Changes

Effect

Phenotype
Activity

Class†

Activity
Score

Single nucleotide variants and indels
*1

198 (32%)

N/A

N/A

Normal

NM

1

*2

91 (14.7%)

2850C>T, 4180G>C

R296C; S486T

Normal

NM

1

*33

5 (0.8%)

2483G>T

A237S

Normal

NM

1

*35

37 (6%)

31G>A, 2850C>T,
4180G>C

V11M; R296C;
S486T

Normal

NM

1

*39

1 (0.2%)

1661G>C, 4180G>C

S486T

Normal

NM

1

*43

2 (0.3%)

77G>A

R26H

Normal

NM

1

*9

21 (3.4%)

2615_2617delAAG

K281del

Decreased

IM

0.5

*10

15 (2.4%)

100C>T, 4180G>C

P34T; S486T

Decreased

IM

0.5

1023C>T, 2850C>T,
4180G>C
1659G>A, 2850C>T,
3183G>A, 4180G>C
2850C>T, 2988G>A,
4180G>C

T197I; R296C;
S486T
V136I; R296C;
V338M; S486T

Decreased

IM

0.5

Decreased

IM

0.5

Splicing defect

Decreased

IM

0.5

*17

4 (0.6%)

*29

1 (0.2%)

*41

69 (11.2%)

*59

5 (0.8%)

2291G>A, 2850C>T,
2939G>A, 4180G>C

Decreased mRNA
expression; R296C;
S486T

Decreased

IM

0.5

*3

7 (1.1%)

2549delA

Frameshift

None

PM

0

*4

85 (13.8%)

100C>T, 1846G>A,
4180G>C

Splicing defect

None

PM

0

*6

4 (0.6%)

1707delT

Splicing defect

None

PM

0

3 (0.5%)

1973_1974insG,
1978C>T, 1979T>C,
2850C>T, 4180G>C

Frameshift

None

PM

0

Two active genes

Increased

UM

2

Two active genes

Increased

UM

2

Normal

NM

1

Decreased

IM

0.5

Two inactive genes

None

PM

0

Two inactive genes

None

PM

0

CYP2D6 deleted

None

PM

0

*20

Structural variants
*1x2

3 (0.5%)

*2x2

4 (0.6%)

*41x2

1 (0.2%)

*36+*10

2 (0.3%)

*4N+*4

4 (0.6%)

*68+*4

33 (5.3%)

*5

23 (3.7%)

Duplication of
CYP2D6*1
Duplication of
CYP2D6*2
Duplication of
CYP2D6*41
*10 in tandem with
CYP2D7/CYP2D6 hybrid
gene
*4 in tandem with
CYP2D7/CYP2D6 hybrid
gene
*4 in tandem with
CYP2D7/CYP2D6 hybrid
gene
CYP2D6 deleted

Two decreased
activity genes
One decreased
activity and one
inactive gene

† UM: ultrarapid metabolizer, NM: normal metabolizer, IM: intermediate metabolizer, PM: poor metabolizer

64

2.5.3

Table 3. CYP2D6 diplotypes (n = 309) identified in liver bank samples

Diplotype
1 / 1x2
2 / 1x2
35 / 2x2
41 / 2x2
1 / 33
2 / 33
1 / 35
2 / 35
1/1
1/2
2/2
35 / 35
4 / 1x2
4 / 2x2
10 / 35
1 / 41
2 / 41
1 / 59
2 / 59
1/9
1 / 10
1 / 17
2/9
10 / 41x2
29 / 39
35 / 41
4 / 33
4 / 35
5 / 35
6 / 35
9 / 41
3 / 43
4 / 43
1/3
1/4

n
1
1
1
2
2
1
12
2
29
35
5
1
1
1
4
18
14
1
3
8
8
3
1
1
1
8
1
3
1
1
6
1
1
2
26

Activity score
3
3
3
2.5
2
2
2
2
2
2
2
2
2
2
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1
1
1
1
1
1
1
1
1

Diplotype
1/5
1/6
1 / 20
2/3
2/4
2/5
2/6
9/9
1 / 4 + 68
1 / 4N + 4
10 / 10 + 36
2 / 4 + 68
20 / 35
35 / 4 + 68
41 / 41
41 / 59
4N + 4 / 33
4 / 41
5 / 41
6 / 41
4/9
4 / 10
4 / 17
4 + 68 / 10 + 36
41 / 4 + 68
41 / 4N + 4
9 / 4 + 68
3/5
4/4
4/5
4 / 20
3 / 4 + 68
4 / 4 + 68
5 / 4 + 68
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n
8
1
1
1
13
4
1
1
12
2
1
5
1
2
1
1
1
10
3
1
3
1
1
1
3
1
1
1
7
4
1
2
5
2

Activity score
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0
0
0
0
0
0
0

2.5.4

Table 4. Multiple linear regression: comparison of association between
CYP2D6 activity and activity score when activity score is assigned using
SNV/indel data only (A) and SNV/indel plus structural variation data (B)

A. Prediction of CYP2D6 activity using activity scores assigned based on SNV/indel data
only
Metoprolol
SE
1.340
1.230
1.290
1.160
1.370
1.690
1.340
285

β
p
Intercept
10.513
< 0.001
AS 0
-10.778
< 0.001
AS 0.5
-9.582
< 0.001
AS 1
-6.234
< 0.001
AS 1.5
-3.420
0.013
AS 2
0.977
0.564
Site: UW
5.252
< 0.001
Degrees of freedom
R2 / adj.
0.3149 / 0.3005
R2

β
61.056
-65.220
-58.369
-42.609
-32.548
-11.587
30.554

Dextromethorphan
SE
6.160
6.040
6.000
5.480
6.220
7.540
6.160
302

p
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.1253
< 0.001

0.3643 / 0.3516

B. Prediction of CYP2D6 activity using activity scores assigned with Stargazer, based on
both SNV/indel and structural variation data
Metoprolol
Dextromethorphan
β
SE
p
β
SE
p
Intercept
10.917
1.280
< 0.001
62.506
5.840
< 0.001
AS 0
-11.074
1.180
< 0.001
-66.055
5.720
< 0.001
AS 0.5
-9.957
1.230
< 0.001
-59.781
5.920
< 0.001
AS 1
-6.154
1.150
< 0.001
-42.283
5.310
< 0.001
AS 1.5
-4.357
1.260
< 0.001
-36.042
5.680
< 0.001
AS 2
1.298
1.720
0.450
-9.978
7.580
0.190
AS 2.5
12.840
1.210
< 0.001
30.092
8.060
< 0.001
AS 3
-2.735
4.110
0.506
-15.124
26.430
0.570
Site: UW
4.848
1.280
< 0.001
29.105
5.840
< 0.001
Degrees of freedom
283
300
R2 / adj.
0.3636 / 0.3456
0.407 / 0.3912
R2

66

2.5.5

Table 5. Multiple linear regression: association between CYP2D6 activity
and activity score, POR protein content, and AKR1D1 mRNA content

Intercept
AS 0
AS 0.5
AS 1
AS 1.5
AS 2
AS 2.5
AS 3
Site: UW
POR protein
AKR1D1 mRNA
Degrees of
freedom
R2 / adj. R2

β
4.540
-11.162
-9.147
-5.277
-3.993
1.660
12.219
-0.569
4.396
0.185
0.038

Metoprolol
SE
1.792
1.452
1.393
1.090
1.299
1.727
0.593
2.898
1.221
0.034
0.012

p
0.012
< 0.001
< 0.001
< 0.001
0.002
0.338
< 0.001
0.845
< 0.001
< 0.001
0.002

223
0.4712 / 0.4474
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Dextromethorphan
β
SE
p
38.133
7.316
< 0.001
-68.953
7.112
< 0.001
-58.065
6.508
< 0.001
-39.621
5.240
< 0.001
-37.050
5.697
< 0.001
-9.388
7.694
0.224
41.358
2.468
< 0.001
-7.004
22.916
0.760
27.737
5.739
< 0.001
0.697
0.136
< 0.001
0.218
0.053
< 0.001
237
0.505 / 0.4941

2.6 Figures
2.6.1

Figure 1. Comparison of diplotype and activity score changes assigned with
SNV/indel data alone and with inclusion of structural variation data with
Stargazer.
SNV data alone
Diplotype
AS

*1/*1
*2/*2
*35/*35
*41/*41
*4/*10
*3/*3
*4/*4
*1/*1
*1/*2
*2/*35
*2/*41
*1/*4
*2/*4
*10/*41
*1/*4
*2/*4
*4/*35
*4/*33
*10/*10
*4/*9
*4/*10
*4/*41
*3/*4
*4/*4
*4/*4

SNV + structural variation data
n
Diplotype
AS
n
Deletion
2
38 *1/*5
ê
1
8
2
9 *2/*5
ê
1
4
2
2 *5/*35
ê
1
1
1
4 *5/*41
ê 0.5 3
0.5
4 *4/*5
ê
0
2
0
1 *3/*5
è
0
1
0
16 *4/*5
è
0
2
Duplication
2
38 *1/*1x2
é
3
1
2
36 *1x2/*2
é
3
1
2
3 *2x2/*35
é
3
1
1.5 16 *2x2/*41
é 2.5 2
1
41 *1x2/*4
é
2
1
1
19 *2x2/*4
é
2
1
1
1 *10/*41x2
é 1.5 1
Hybrid tandem
*1/*68 + *4
è
1
12
1
41
*1/*4N + *4
è
1
2
1
19 *2/*68 + *4
è
1
5
1
5 *35/*68 + *4
è
1
2
1
2 *4N + 4/*33
è
1
1
1
1 *10/*36 + *10
è
1
1
0.5
4 *9/*68 + *4
è 0.5 1
0.5
4 *36 + *10/*68 + *4
è 0.5 1
*41/*68 + *4
è 0.5 3
0.5 14
*4N + *4/41
è 0.5 1
0
2 *3/*68 + *4
è
0
2
0
16 *4/*68 + *4
è
0
5
Deletion + hybrid tandem
0
16 *5/*68 + *4
è
0
2

Columns on the left show selected diplotypes and activity scores (AS) assigned using allele calls from SNV/indel-only
data. Corrected diplotypes and activity scores, based on Stargazer allele assignments, are displayed in the columns on
the right. Activity scores are color-coded: 3 and 2.5 (dark green), 2 (green), 1 (yellow), 0.5 (orange), and 0 (red).
Arrows indicate the direction of the change in activity score assignment with the incorporation of structural data:
decrease (↓), increase (↑), and no change (→).
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2.6.2

Figure 2. Association between CYP2D6 metabolite formation rate and
CYP2D6 activity score.

Panels A and B show alpha-hydroxymetoprolol formation rate by activity score assigned with SNV/indel data alone
(panel A) and with Stargazer (panel B). Panels C and D show dextrorphan formation rate formation rate but activity
score assigned with SNV/indel data alone (panel C) and with Stargazer (panel D).
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2.6.3

Figure 3. Association between CYP2D6 metabolite formation rate and
CYP2D6 mRNA and protein content.

CYP2D6 metabolite formation rate was associated with CYP2D6 mRNA content quantitated by RNASeq: alphahydroxymetoprolol formation rate (panel A) and dextrorphan formation rate (panel B); CYP2D6 metabolite formation
rate was associated with CYP2D6 protein content quantitated by LC-MS/MS: alpha-hydroxymetoprolol formation rate
(panel C) and dextrorphan formation rate (panel D).
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2.6.4

Figure 4. Association between CYP2D6 metabolite formation rate and POR
protein and AKR1D1 mRNA content.

CYP2D6 metabolite formation rate was associated with POR protein content quantitated by LC-MS/MS: alphahydroxymetoprolol formation rate (panel A) and dextrorphan formation rate (panel B); CYP2D6 metabolite formation
rate was associated with AKR1D1 mRNA content quantitated by RNASeq: alpha-hydroxymetoprolol formation rate
(panel C) and dextrorphan formation rate (panel D).
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3 Discussion
3.1 Project summary
The goal of my research was to identify rare coding and structural variation that
affects CYP2D6 activity that is not yet routinely included in pharmacogenetic tests used
in the clinic and demonstrate how the variants can improve the predictive ability of
CYP2D6 activity score. To accomplish this goal, I used human liver microsomes and
DNA sequencing data derived from a human liver bank to determine the correlation
between activity score and CYP2D6 before and after incorporating structural and copy
number variation data derived from the Stargazer platform.
In Specific Aim 1, I used data from the PGRNseq platform to assign diplotypes to
309 human liver bank donors. Part of this aim was to identify rare variants of functional
consequence. While I did identify uncommon (<5% allele frequency) and rare (<1%
allele frequency) variants, none of them appeared to cause a dramatic change in activity.
The alleles that I identified in the liver bank samples occurred at frequencies that
reflected the mostly-European demographics of the donors.
In Specific Aim 2, I used human liver microsomes (HLMs) as an in vitro model to
determine CYP2D6 activity. For probe drugs, I chose to use dextromethorphan because it
is well established as a probe in the CYP2D6 literature and metoprolol because of its
clinical relevance. Using the metabolite formation rates from the HLM incubations, I
found that activity score explained 31% (using metoprolol) to 36% (using
dextromethorphan) of the variability in CYP2D6 activity in the liver bank samples when
diplotypes were assigned using SNV and indel data alone.
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Specific Aim 3 was added after Specific Aims 1 and 2 were complete. I used
structural and copy number variation data from the Stargazer algorithm to assign new
diplotypes to samples that could not be identified as having structural variations based on
SNVs and indels alone. Approximately 20% of the samples were assigned new
diplotypes and 8% were assigned a new activity score as a result.
After seeing these changes in activity score assignments, the next step was to assess
whether activity score was actually more predictive of CYP2D6 function. When
diplotypes were reassigned based on the Stargazer algorithm that utilizes both SNV/indel
and structural variation data, this amount of variability in CYP2D6 activity explained by
activity score increased to 36% for metoprolol and 41% for dextromethorphan.
I then created a multiple linear regression model using the activity data generated in
Specific Aim 2 and activity scores given to the Stargazer-updated diplotypes as well as
additional data available for the liver samples: liver collection site, POR protein content,
and AKR1D1 mRNA content. With the additional data, the model explained around 47%
(using metoprolol) to 50% (using dextromethorphan) of the observed variation in
CYP2D6 activity.
There are two conclusions that stand out above the rest. The major conclusion is that
the inclusion of structural and copy number variation in pharmacogenetic tests is
extremely important. Incorporation of structural and copy number variation data with
sequence data will help identify extreme phenotypes (e.g. poor and ultrarapid
metabolizers) and will improve the predictive power of activity score. CYP2D6*5, the
allele representing a deletion of the CYP2D6 gene, occurs at a frequency of
approximately 6% in African populations, 5% in East Asian and Oceanian populations,
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and around 2-3% in European, South/Central Asian, and Middle Eastern populations. At
the low end of the range, a 2% allele frequency means that 4% of the population carries
the *5 allele. At the high end, an allele frequency of 6%, around 11% of the population
carries *5. This represents a large number of people that will be incorrectly genotyped if
copy number variation is not included on a pharmacogenetic test. Incorrect classification
of a poor metabolizer can have serious clinical ramifications. If, for example, a poor
metabolizer is given a starting dose of a tricyclic antidepressant appropriate for an normal
metabolizer, they are at higher risk of adverse effects such as confusion, muscle twitches,
hypotension, and arrhythmias. 60,85,105 Ultrarapid metabolizer phenotypes are generally
due to the presence of additional CYP2D6 gene copies. The *1xN allele is particularly
common on Oceanian populations, occurring at a frequency of nearly 12%. Duplications
are also relatively common Middle Eastern populations; *1xN occurs at a frequency of
3.1% and *2xN at 3.9%. This translates to over 20% of Oceanian individuals carrying a
*1xN allele and around 6 and 8% of Middle Eastern individuals carrying a *1xN and
*2xN allele, respectively. If an ultrarapid metabolizer is misclassified and, for example, is
prescribed codeine, they are at higher risk of experiencing adverse effects such as
oversedation or respiratory depression. 85,101
The second, more minor conclusion is that considering POR pharmacogenetics along
with CYP2D6 pharmacogenetics may offer a way to improve the accuracy of CYP2D6
activity predictions. With a clinical setting in mind, the logistics would be simple since
samples could be collected for POR and CYP2D6 pharmacogenetic tests at the same time.
Interpretation of how both POR and CYP2D6 diplotypes impact CYP2D6 activity would
require further study. A starting point would be to investigate the impact of POR
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pharmacogenetics on CYP2D6 activity using the liver bank samples. A study examining
the effects of various recombinant POR variants on CYP2D6 activity found that POR
with common variant A503V decreased CYP2D6 activity by 40-50% when using
dextromethorphan and bufurolol as probes.90 The POR A503V variant, also known as
POR*28, is common and is present at frequencies ranging from 19 – 37% across world
populations.106
In conclusion, CYP2D6 is a highly relevant, highly polymorphic, highly complicated
gene. When using pharmacogenetic data to make predictions about CYP2D6 activity,
analysis of SNVs and indels alone is not sufficient. The inclusion of structural variation
data improves the precision of CYP2D6 pharmacogenetic tests and is key to avoiding
adverse effects or treatment failure in poor and ultrarapid metabolizers.

3.2 Emerging roles for pharmacists
Pharmacists can play essential roles in the clinical implementation of
pharmacogenetic testing. As members of the healthcare team, they are uniquely qualified
to act as translators of pharmacogenetic test results into actionable treatment
recommendations.
3.2.1

Physician knowledge gaps

A major barrier to the clinical implementation of pharmacogenomics is a lack of
physician knowledge. In a 2014 survey of US-based primary care physicians,
cardiologists, and psychiatrists, only 12.6% reported being extremely or very familiar
with pharmacogenomics. Of the physicians who had never ordered a pharmacogenetic
test, common reasons were not knowing what test to order (69.7%) and being unsure
about the clinical value of testing (51.9%).107 A previous study reported similar results,
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with only 13% of surveyed physicians stating that they felt well-informed about the role
of pharmacogenomic testing in therapeutic decision-making. 108 A reason for this
knowledge deficit is a lack of training in pharmacogenomics; only 11% of the
respondents in the 2014 survey reported that they had received formal training in the
topic. 107
Physicians who are active participants in the pharmacogenomics implementation
program at the Vanderbilt University School of Medicine also reported these types of
knowledge deficits. Of 15 clinicians interviewed, a common theme was that it is difficult
for them to keep up on current pharmacogenetics evidence and recommendations. Some
also expressed difficulty with explaining the rationale behind pharmacogenetic testing to
patients and their families.109
3.2.2

Pharmacist qualifications

Schools of pharmacy have begun filling in the pharmacogenomics knowledge gap by
expanding the pharmacogenetics content in their curricula; the percentage of schools with
pharmacogenetics curriculum has increased from 39% in 2005 to 89% in 2010. The
Accreditation Council for Pharmacy Education (ACPE) has since made
pharmacogenetics a required curricular component for all accredited pharmacy schools,
listing it in their 2016 blueprint as a factor that should be emphasized in “evidence-based
clinical decision making, therapeutic treatment planning, and medication therapy
management strategies.”110 Professional societies have also recognized the opportunity
for pharmacist involvement with clinical pharmacogenomics. For example, the American
Society of Health-System Pharmacists (ASHP) released an official position statement,
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explaining that due to their “distinct knowledge, skills, and abilities,” pharmacists should
“lead efforts to guide optimal drug selection and drug dosing based on those results.”111
On a basic level, clinical pharmacists use patient-specific data to advise physicians
on optimal drug therapy for a particular patient. In a 2013 survey of pharmacists working
in United States hospitals, 98% of pharmacists provided formal recommendations on
dose adjustments, 93% provided drug information, and 92% were responsible for
pharmacokinetics monitoring.112 The interpretation of pharmacogenetic test results into
treatment recommendations is just another variation on this theme and fits neatly into
pharmacists’ preexisting workflows: if a patient’s creatinine clearance is below a certain
level, decrease the dose of drug X. If their potassium level is too high, switch to drug Y.
If they are a CYP2D6 poor metabolizer, avoid drug Z.
The utility of pharmacists in specialized clinical roles has been well-established in
areas such as anticoagulation, smoking cessation, transition of care medication review,
and disease state management for chronic conditions like asthma, hypertension,
hyperlipidemia, and diabetes. 112,113 These programs are effective at improving patient
outcomes. As reported in a 2015 meta-analysis on the effectiveness of clinical pharmacy
services, anticoagulation programs significantly reduced the risk of total bleeding events
(RR 0.51, 95% CI 0.28 – 0.94), hypertension management programs resulted in systolic
blood pressure reductions of 8 – 11 mmHg, diabetes management programs resulted in
HbA1c reductions of 0.9 – 2.1%, and hyperlipidemia programs resulted in a mean total
cholesterol reduction of 22 mg/dL.113
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3.2.3

Pharmacist roles in existing pharmacogenomics programs

Institutions such as St. Jude Children’s Research Hospital and University of Florida
have designed pharmacogenomics implementation programs that rely on pharmacist
input.
At St. Jude Children’s Research Hospital, pharmacists have roles throughout the
pharmacogenetic testing process.114 After diplotype results are available from the
laboratory, a pharmacist manually reviews them for each patient and writes a consult note
that includes a phenotype assignment, diplotype interpretation, dosing recommendations,
activity score (if CYP2D6 was tested), and a link to online resources for more
information. The pharmacist also performs a medication reconciliation to assess whether
the patient is taking a medication with a relevant pharmacogenetic association. A second
pharmacist reviews all information prior to inclusion in the electronic medical record. All
new pharmacist hires at St. Jude receive training in pharmacogenetics as part of their
initial required competencies and complete refresher courses every three years. In
addition to training on test interpretation and dosing recommendations, pharmacists are
also educated on how to discuss pharmacogenetic test results with patients and their
families.114
University of Florida’s Personalized Medicine Program was developed and is run
primarily by pharmacists in a wide range of roles.112 A unique aspect of this program is
that whenever a prescriber encounters a point of care alert about a pharmacogenetic
association, a clinical pharmacist is notified via an inbox message. This allows the
pharmacist to coordinate care in-person with the prescriber or provide direct patient care,
if needed. To keep abreast of current pharmacogenetics research, a dedicated pharmacist
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is responsible for reviewing new literature, integrating relevant findings into practice, and
providing ongoing clinical education. The program also has a PGY2 pharmacy resident
who is responsible for monitoring medication safety trends and providing education, data
management, and logistical support to prescribers.112
3.2.4

Expansion beyond academic medical centers
Currently, most pharmacogenomics implementation programs are based at large

academic medical centers. In order to reach patients who don’t have access to these
facilities, a reasonable next step is implementation in primary care settings. As
approximately 80% of primary care visits result in drug prescriptions, pharmacogenetic
testing has great potential for widespread benefit.115 Thus far, very few studies have
evaluated the feasibility of using pharmacogenetics in primary care. Preliminary results,
however, are promising.
At two family practice offices on Vancouver Island and three family practices and
one pharmacy in metropolitan Vancouver, British Columbia, 191 patients were enrolled
in a study to assess the ability to obtain DNA samples, genotype them, and link the
results to decision support software.116 Saliva samples were collected using the Oragene
DNA collection kit and transported to a laboratory at the University of British Columbia
by research staff, mail, or float plane. The DNA was extracted and genotyped using a
custom TaqMan panel developed based on genetic variants with the highest levels of
clinical evidence for use in primary care. Of the 191 total patients, 185 were successfully
genotyped for all genes on the panel. Actionable diplotypes for drugs included in the
decision support software were found in 179 (96.8%) of the patients, which is similar to a
previous study that found actionable variants in 96% of a 5000 patient cohort. Results
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were uploaded into dedicated medication decision support software (MDSS) and reports
were distributed directly to each patient’s pharmacist or physician. Over a course of 3
months, pharmacists and physicians accessed the software 236 times, most frequently to
obtain therapy recommendations for hyperlipidemia (n = 53) and hypertension (n =
52).116 This study is particularly interesting because it illustrates how the authors
addressed the barriers associated with geographically remote clinic sites and electronic
healthcare record fragmentation. Instead of excluding patients who lived on Vancouver
Island, a system was established to transport samples via float plane. To overcome the
informatics challenges of integrating pharmacogenetics data into electronic medical
records, software that operates independently of the electronic medical record was
developed.
In any setting, implementation of pharmacogenetics requires accurate genotyping
data, leadership by knowledgeable healthcare professionals (best embodied by
pharmacists), and some creative problem solving. We have all the pieces and now is the
time to put them together.
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4 Appendix: optimization of human liver microsome
incubations
As discussed in section 1.3.2.1, optimization of human liver microsome incubations
requires selection of appropriate drug concentration, HLM protein concentration, and
incubation time. Since these parameters are interdependent, only one parameter can vary
at a time while the others are held constant for optimization assays. For early
optimization experiments, a matrix design was used to try several combinations of drug
concentrations, protein concentration, and incubation times. Then, specific parameters
were explored more in-depth if needed. Pooled human liver microsomes (Xenotech) were
used for optimization assays.

4.1 Selection of probe drugs and drug concentrations
Dextromethorphan and metoprolol were selected for use as probe drugs.
Dextromethorphan is a classic CYP2D6 probe substrate for in vitro assays and has been
used as such since the late 1980s.117,118 CYP2D6 catalyzes the O-demethylation of
dextromethorphan to dextrorphan and is responsible for 80% of total dextrorphan
formation, with CYP3A4 also contributing when dextromethorphan concentrations are
above 50 µM.119 Metoprolol is not as widely used as a CYP2D6 probe drug but was
selected because of the clinical evidence in favor of a pharmacogenetic association. A
meta-analysis of 11 clinical trials that included a total of 264 participants found a 5.3-fold
difference in peak plasma metoprolol concentration between CYP2D6 poor metabolizers
and ultrarapid metabolizers, as well as a 13-fold difference in area under the curve and a
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15-fold difference in apparent oral clearance.120 CYP2D6 is exclusively responsible for
the alpha-hydroxylation of metoprolol to alpha-hydroxymetoprolol.121
Because a metabolite formation assay approach was selected, probe drug
concentrations were required to be below Km to ensure that the reaction stayed in the
linear range of the Michaelis-Menten curve. The concentration cannot be too low,
however, because an underlying assumption of the assay is that substrate concentrations
must remain high relative to enzyme concentrations. Generally, this assumption holds
true if no more than 10% of the substrate is depleted over the course of an incubation.122
For each substrate, we searched the literature for the lowest published Km values,
selected based on data compiled in the University of Washington Drug Interaction
Database (https://didb.druginteractioninfo.org/). In initial assays, we chose a range of
drug concentrations that bracketed these literature Km values of 2.8 µM for
dextromethorphan and 21.6 µM for metoprolol.

4.2 Selection of HLM protein concentrations and incubation times
Typical HLM protein concentrations for incubation assays are in the range of 0.1 –
0.5 mg/mL, but this was not feasible with our limited allocation of HLMs. Based on
consultation with our collaborator who quantified the metabolites (section 2.2.2.5), we
started with protein concentrations of 50 µg/reaction (0.05 mg/mL) using pooled HLMs
and metoprolol at a range of concentrations that bracketed the literature Km of ~20 µM: 2
µM (1/10 Km), 4 µM (1/5 Km), 10 µM (1/2 Km), 20 µM (Km), and 40 µM (2 Km).
In general, incubation times of 5 – 10 minutes will result in linear reactions with
detectable metabolites.123 Because we were limited by low HLM protein concentrations,
we tried longer incubation times to ensure the production of sufficient detectable
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metabolite. Longer incubations may result in enzyme or substrate degradation or
inhibitory effects due to accumulation of metabolites, so we tried a range of incubation
times to see if we saw any evidence of these effects at longer timepoints. For the initial
metoprolol assay discussed above, incubation times were 5, 15, and 30 minutes.
The metabolite of interest, alpha-hydroxymetoprolol, was detected at every
metoprolol concentration and timepoint. At all three timepoints, nonlinearity started to be
observed around a metoprolol concentration of 20 µM. Substrate depletion was above
10% for the incubations using 2 µM of metoprolol at 15 and 30 minutes. Thus, acceptable
parameters were 2 µM metoprolol + 5 minutes; 4 µM + 5, 10, or 15 minutes; and 10 µM
metoprolol + 5, 10, or 15 minutes.
Because we saw ample metabolite formation using 50 µg of pooled HLM protein,
we did a similar assay to see if it was feasible to use 20 µg per reaction well. Metoprolol
was used at 2 µM and 4 µM at incubation times of 15, 30, and 45 minutes. Longer
incubations were tested to account for lower HLM protein concentrations. The rate of
alpha-hydroxymetoprolol formation was linear with respect to substrate concentration
and time. Substrate depletion remained below 10% for both substrate concentrations at all
timepoints. The assay was repeated for confirmation and similar results were obtained.
From these optimization assays, we selected the following parameters to use with
the liver bank samples: 20 µg HLM protein, 4 µM metoprolol, and 30 minute incubation
time. These parameters produced a linear reaction with 1.14% of substrate depleted over
the course of the incubation.
Optimization of incubations using dextromethorphan as a probe drugs were
performed similarly. We selected a range of dextromethorphan concentrations that
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bracketed the literature Km (2.8 µM, rounded up to 5 µM to simplify calculations). These
concentrations were 0.5 µM (1/10 Km), 1.25 µM (1/4 Km), 2.5 µM (1/2 Km), 5 µM (Km),
and 10 µM (2 Km). Incubation times were 10, 20, and 30 minutes and each reaction well
used 20 µg HLM protein.
The metabolite formation curve appeared linear at metoprolol concentrations
below 2.5 µM at every timepoint. The assay was repeated using dextromethorphan at
concentrations of 0.5 µM, 1.25 µM, and 2.5 µM and incubation times of 10, 20, and 30
minutes. Dextrorphan formation was linear over time when dextromethorphan was used
at concentrations of 0.5 µM and 1.25 µM, but not 2.5 µM.
From these optimization assays, we selected the following parameters to use with
the liver bank samples: 20 µg HLM protein, 1.5 µM dextromethorphan, and 20 minute
incubation time. Approximately 7% of substrate was depleted over the incubation time
with these parameters. Dextromethorphan was used at 1.5 µM rather than 1.25 µM
because it was easier to accurately measure the volume of stock solution needed for the
assay. A 20 minute incubation time was selected because a longer incubation was not
needed to produce quantifiable metabolite.
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